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CHAPTER 1 
Imroduction 
WhaJ is the evidence that hyperammonemia causes hepatic encephalopathy? 
Robert J. de Knegt, Soll<O W. Schalm 
Deparnnent of Internal Medicine II and Hepatogastroenterology 
University Hospital Dijkzigt, Erasmus University Rotterdam, the Netherlands 
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INTRODUCTION 
Despite our expanding insight into brain function (and dysfunction) and the yearly 
production of several hundreds indexed papers on hepatic encephalopathy, our 
understanding of the syndrome has improved only marginally. The recognition of the 
syndrome of portosystentic encephalopathy in tbe fifties stimnlated a search for gut-
derived substances !bat conld reach tbe brain because of defective hepatic clearance (1). 
At first ammonia was considered the prime neurotoxin. However, the ammonia hypothesis 
was rejected by many because the correlation between plasma ammonia level and degree 
of encephalopathy was found to be poor and tberapy aiming at lowering increased plasma 
ammonia concentrations in patients was often ineffective. New theories on the 
patbogenesis witb implications for treatment were developed, but -unfortunately-
prontising new approaches to treatment (branched chain amino acids, hemoperfusion, 
hepatocyte transplantation, benzodiazepine antagonists) have not yet yielded convincing 
results. Currently there is renewed interest for ammonia and its role in the pathogenesis 
of hepatic encephalopatby. 
For a substrate to be considered a toxin relevant for the development of hepatic 
encephalopatby three criteria should be fullfilled (2): 1. tbe toxin should be present in 
abnormally high amounts in tbe presence of hepatic encephalopatby, 2. adntinistration of 
tbe toxin should induce hepatic encephalopatby, and 3. correction of the abnormality 
should reverse hepatic encephalopatby. In tbe following discussion tbese criteria will be 
applied to ammonia. 
Ammonia should be present in abnormal amounts in the presence of hepatic 
encephalopathy. 
Blood ammonia concentrations are usually elevated in patients with liver disease 
witb or witbout hepatic encephalopatby (3-7). Plasma ammonia levels tend to increase 
witb tbe degree of hepatic encephalopatby (8,9) and frequently correlate well witb tbe 
changing neuropsychiatric status in tbe individual patient (9, 1 0). Cerebrospinal fluid 
glutamine levels, tbe cerebral metabolic end product of ammonia, have been shown to 
correlate closely with tbe degree of encephalopatby (11·14). Besides portoSYstentic 
encephalopatby tbere are otber hyperammonentia syndromes (inherited urea cycle enzyme 
deficiency syndromes (15), inherited organic acidentias (15), transient hyperammonentia 
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in premature infants (16,17), Reye's syndrome (18,19) and valproic acid induced 
hyperannnonemia (20)), all of which are associated with high plasma ammonia levels and 
encephalopathy. 
In experimental hepatic encephalopathy in the rat from acute ischemic liver failure, 
a clear correlation between the brain ammonia concentration and the neurological status 
exists (21). In addition, most other currently accepted animal models used for the study of 
hepatic encephalopathy universally demonstrate the coexistance of elevated plasma and 
brain ammonia concentrations (22,23). Canine congenital portosystemic encephalopathy is 
a "spontaneous animal model" characterized by many of the pathological features of 
chronic hepatic encephalopathy in man, including elevated plasma ammonia levels 
(24,25). See table L 
Thus, ammonia appears to be present in abnormally high amounts in both clinical 
and experimental hepatic encephalopathy. However, in the clinical condition the 
correlation between plasma ammonia level and degree of encephalopathy is often found to 
be poor (8,9). Because of tltis poor correlation, and the description of comatose patients 
with normal plasma ammonia levels (4,8), many tend to reject the ammonia hypothesis on 
the development of hepatic encephalopathy. There are, however, several reasons for tltis 
discrepancy. First, arterial plasma ammonia levels indicate the ammonia delivery to the 
brain, but do not give information about the brain ammonia concentration. In addition, in 
liver disease there is increased entrance of ammonia into the brain, which may cause 
ammonia induced encephalopathy even though arterial ammonia levels are only slightly 
elevated (26). The strong correlation between cerebrospinal fluid levels of glutamine and 
degree of encephalopathy supports tltis view. Second, a strong correlation between plasma 
ammonia and degree of encephalopathy would implicate simple, direct toxic effects of 
ammonia on brain function, whereas it is more likely that ammonia interferes with normal 
brain function through the induction of a variety of disturbances which need time to 
become expressed and to resolve. The observation that the blood ammonia level 
frequently correlates well with the changing neuropsychiatric status in the individual 
patient favours tltis concept (9, 1 0). Third, patients with severe liver disease can develop 
liver failure associated complications like renal failure (27,28), acid-base and electrolyte 
disturbances (29) and infections (30), which by themselves may induce or aggravate 
metabolic/hepatic encephalopathy thus masking a probable correlation between plasma 
ammonia and degree of encephalopathy (31). In addition, the number of patients with 
liver disease prescribed hypnotics, sedatives, analgesics or tranquilizers should not be 
overlooked (pseudo-encephalopathy)(32). 
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TABLE I 
Experimental hepatic encephalopathy from acute liver failure 
Species Model 
Rabbit Ischentia 
Galactosamine 
Hepatectomy 
Rat Ischemia 
CCL, 
Hepatectomy 
Galactosamine 
Dog Paracetamol 
Pig Ischentia 
- not measured 
First author 
(reference) 
De Knegr (42) 
Blitzer (80) 
Berlinger (81) 
Bosman (22) 
Yamamoto (82) 
Scbalm (83) 
Zeneroli (23) 
Plasma ammonia Brain ammonia 
j.<mOl/1 J.<ffiOI/1 
450-700 
150-200 
600-800 
700-1000 1000-1500 
250-400 
600-1100 
1500-4000 
Francavilla (84) 400-650 
De Groot (85) 300-700 
None of these different causes can be deduced from the clinical symptoms of 
encephalopathy in the individual patient, because no presentation of encephalopathy is 
specific, or in other words coma is coma (32). In conclusion, hepatic encephalopathy is 
usually accompanied by elevated plasma ammonia levels and the blood ammonia level 
frequently correlates well with the changing neuropsychiatric status in the individual 
patient. A poor correlation between plasma ammonia and degree of encephalopathy can 
probably be explained by the diverse toxic actions of ammonia which need time to 
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become expressed and to resolve, and by the coexistence of other liver failure associated 
complications which by themselves may induce or aggravate encephalopathy. In case of 
normal or near normal plasma ammonia levels in patients with encephalopathy, there may 
be increased ammonia entry into the brain or there may be pseudo-encephalopathy. 
Induction of the abnormality, i.e. the administration of ammonia, should induce 
hepatic encephalopathy. 
In the fifties it was observed that the administration of ion exchange resins which 
liberate ammonia in the gut posed patients with liver cirrhosis at increased risk for the 
development of hepatic encephalopathy (33). Van Caulaert eta!. (34) were the first to 
observe that ammonium chloride ingestion precipitated hepatic encephalopathy in patients 
with liver cirrhosis. These experiments have been repeated, yielding seemingly conflicting 
results (table ll). From these studies it becomes apparent that one single dose of 30-90 
mmol ammonia (i.e. ca. 0.5-1.5 mmolfkg body weight) does not have important 
immediate effects on clinical symptoms (9 ,35 ,36), pyschometric performance (37) or the 
electroencephalogram (38). However, such a dose may give rise to clinical symptoms of 
encephalopathy after several hours (8). Larger doses given for a longer period induce 
severe signs of encephalopathy in all patients with liver cirrhosis (1,39). It can thus be 
concluded that ammonia induces encephalopathy in patients with liver cirrhosis, the 
occurrence depending on dose and duration. 
Infusion of ammonia into rabbits, simulating the plasma ammonia levels of acute 
ischemic liver failure, induces an encephalopathy with many of the characteristics of 
encephalopathy from acute liver failure (40). At present there are no other extensive 
studies on experimental hyperammonemia. However, from the limited description of 
experimental hyperammonemia found in the literature, discrepancies between 
experimental hepatic encephalopathy and hyperammonemic encephalopathy appear to be 
predominantly determined by the amount and rate of ammonia administration. Bolus 
injections, which give acutely increased plasma ammonia levels, are frequently followed 
by convulsions (32), whereas more gradual increases to levels found in acute liver failure 
induce symptoms like disappearance of spontaneous activity and lethargy which can also 
be observed in hepatic encephalopathy (40,42). See table ill. 
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TABLE II 
Ammonia tolerance tests in patients with liver cirrhosis 
First author 
(reference) 
Marchesini (36) 
Loguercio (37) 
Eichler (35) 
Cobn (38) 
Stahl (9) 
Jonung (86) 
Sununerskill (8) 
Sherlock (1) 
Phillips (39) 
Summerskill (87) 
Ammonia dose 
in mrnol 
601 one bolus 
90/one bolus 
30/ one bolus 
60/one bolus 
60/one bolus 
75-150/in 2 doses 
40-50/one bolus 
50-150/day 
150-225/day 
150-1250/one bolus 
Time of observation Number of patients with 
hepatic encephalopathy/ 
number of patients studied 
45 minutes 2/17 
45 minutes 0/30 
60 minutes 0/3 
60 minutes 0/19 
90 minutes 21170 
6 hours 017 
7 hours 515 
4-6 days 8/8 
4-22 days 9/9 
? 6/6 
Correction of hyperammonemia should reverse hepatic encephalopathy 
ln theory, high blood ammonia should be decreased by the extraction of ammonia 
and/or its substrates, and the inhibition of the involved enzymes. Current therapy is 
directed towards lowering gut -derived toxins, in particular ammonia. Ammonia is formed 
in the bowel by degradation of intestine-derived glutamine, degradation of dietary proteins 
and degradation of urea by urease-producing enteric bacteriae (43). Therefore the 
therapeutic aim is to reduce the degredation of dietary protein, urea and glutamine. The 
theoretical options consist of a low protein diet, the acceleration of the bowel transit time, 
the removal of urease-producing bacteriae from the bowel and the reduction of the body 
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TABLE ill 
Experimental encephalopathy from acute hyperammonemia 
Species Model 
Rabbit Infusion 
Infusion 
Rat Bolusinjections 
Bolusinjections 
PCS +injections 
PCS +infusion 
Urease 
- not measured 
urea pool. 
First author 
(reference) 
De Knegt (42) 
Ferenci (88) 
Zieve (89) 
Zeneroli (23) 
Zieve (89) 
Bosman (90) 
Bosman (22) 
Plasma ammonia Brain ammonia 
JL!IlOI/1 !<IDOl/kg 
600-1000 
250-350 
2000-3750 
3200-5000 
2500-3500 
650-750 2000-2300 
800-1500 1000-2000 
The association between a high protein diet and the occurrence of hepatic 
encephalopathy is well recognized, with the blood anunonia concentration varying with 
the dietary protein content (39,44). The amount of anunonia released from food is 
vruiable (45); the ammonia content of meat is high, whereas the ammonia content of 
vegetarian proteins is low. Indeed in patients with liver cirrhosis vegetarian proteins are 
better tolerated (46). Furthermore a vegetarian diet contains more fibre whicb stimulates 
bowel movements and thereby facilitates the e!hnination of toxic metabolites (47,48). In 
addition bowel cleansing with an enema is also effective in lowering plasma ammonia 
(49,50). Anthnicrobia! drugs like neomycin are known to suppress intestinal bacteria 
responsible for ammonia production, and were subsequently shown to improve the 
menta!state of patients with hepatic encephalopathy (51). 
Lactulose has many therapeutic effects and therefore forms the cornerstone of current 
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treannent of hepatic encephalopathy: it accelerates the bowel transit time, it modifies the 
colonic flora with displacement of urease containing bacteria, it stimulates the 
incorporation of ammonia into the bacterial wall and it inhibits ammonia generation in the 
gut (52). The beneficial effects of lactulose in hepatic encephalopathy were early 
recognized (53); and controlled trials have clearly shown the therapeutic capacity of 
lactulose in hepatic encephalopathy with lowering plasma anunonia levels (54). 
Other promising treatment options are the ammonia flXation and enhancement of renal 
excretion by sodium benzoate (55), and the inhibition of bacterial urease by 
nicotinohydroxamic acid (56). 
Although the benefits of the treannent modalities discussed are greater in patients with 
low-grade hepatic encephalopathy and the application is often less successful in severe 
liver disease (due to increased occurrence of other liver failure associated complications), 
it can be concluded that the current treattnent of hepatic encephalopathy is effective 
mainly through lowering plasma anunonia. 
In conclusion, it appears that anunonia fullfills largely the criteria originally named by 
Zieve (2): I. a patient with hepatic encephalopathy usually has an elevated plasma 
ammonia level, which correlates more or less with the changing mental state; 2. ammonia 
induces encephalopathy in patients as well as in experimental animals, the occurrence and 
presentation of encephalopathy depends on dose and duration; and 3. lowering the 
ammonia production and plasma ammonia ameliorates most cases of hepatic 
encephalopathy. "If the role of ammonia in the genesis of hepatic coma is not yet 
satisfactorily defined, there is no other theory that comes so near to conforming to the 
observed facts" (57). 
AlMS OF TillS THESIS 
The pathogenesis of hepatic encephalopathy is largely unknown. Ammonia was the 
flrst toxin seriously considered to be of importance in the pathogenesis, has been 
subsequently rejected, but now appears to return to the forefront of "hepatic 
neurochemistry" (58). In theory, hyperammonemia can disturb normal brain ftmction 
through interference with basic cell metabolism (e.g. pH-regulation and water and energy 
balance)(59-61), electrophysiologic membrane ftmction (depending on ion pumps)(62) and 
biochemical communication between neurons, i.e. neurotransmission (depending on 
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neurotransmitters). With regard to neurotransmission, one of the current opinions on the 
pathogenesis of hepatic encephalopathy is a dysbalance between neuro-inhibitory and 
neuro-excitatory neurotransmitters (63). Several groups have proposed that neuro-
inhibition via GABA or endogenous benzodiazepines is enhanced; we are investigating 
whether excitatory neurotransmission -especially glutamate neurotransmission- is altered 
during hepatic encephalopathy. 
The metabolism of glutamate, the most important excitatory neurotransmitter in the 
mammalian brain, is linked to that of ammonia (64,65). In neurons the neurotransmitter 
glutamate is produced from glutamine, through the enzymatic action of glutaminase. In 
vitro the activity of glutaminase, which is essential for the formation of glutamate, is 
inhibited by ammonia (66,67). Thus it was assumed that ammonia decreases the amount 
of glutamate in the brain, which probably would have an effect on normal brain function. 
Subsequently, the amount of glutamate was shown to be decreased in autopsied brain 
tissue from patients as well as animals with hepatic encephalopathy (22,68-70). However, 
these were whole brain studies in which the total amount of glutamate was assessed in all 
anatomical compartments together (vascular, intracellular and extracellular). The 
concentration of a neurotransmitter in the synaptic cleft, a part of the extracellular space, 
is probably the best reflection of neurotransmitter function. Since less than 1% of the total 
amount of antino acid in the brain is found in the extracellular space, total brain 
measurements are not suitable for determining neurotransmitter function (71). The brain 
dialysis technique has made the extracellular space more accessible for research (72-75). 
Furthermore, with brain dialysis one can distinguish between glutamate derived from 
basal cell metabolism and that attributable to neurogenic events (76,77). 
The aim of the present investigation was to determine in-vivo whether there is a 
hyperammonemia-induced deficit of the excitatory neurotransmitter glutamate in the 
extracellular space of the brain during encephalopathy from acute liver failure and from 
acute hyperammonemia in the rabbit. 
In our laboratory we have rabbit models for both acute ischemic liver failure and acute 
hyperammonemia (78,79). In the latter model ammonia is infused such that the plasma 
ammonia levels simulate those measured during acute ischemic liver failure (78). 
Because good animals models form a crucial part in experiments to unravel the 
mechanism of ammonia toxicity and its contribution to hepatic encephalopathy, this thesis 
also describes the clinical and biochemical details of our rabbit models for acute ischemic 
liver failure and acute hyperammonemia. 
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Aims of this thesis: 
1. To study, in rabbits, the suitability of experimental acute liver failure and acute 
hyperammonemia simulating acute liver failure for the study of hepatic 
encephalopathy and ammonia toxicity. 
2. To study glutamate neurotransmission in rabbits with acute liver failure and acute 
hyperammonentia. 
3. To determine the role of the changes in glutamate neurotransntission found in 2 in 
the development of hepatic encephalopathy. 
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SUMMARY 
To study the molecular basis of ammonia toxicity highly reproducible models of 
acute liver failure and acute hyperammonemia in the rabbit were developed. Acute liver 
failure was induced by two-stage liver devascularization, and acute hyperamm.onemia by 
prolonged ammonia infusion such that the plasma ammonia pattern found in acute liver 
failure was simulated. Clinical symptoms, spectral analysis of the E.E.G .. biochemistry 
(blood gasses, renal function, electrolytes and markers of hepatic injury) and the presence 
of cerebral edema were studied. During acute liver failure severe encephalopathy 
developed after 10.2±1.9 hours (n=6, mean±SEM). Other liver failure associated 
abnormalities were cerebral edema, lactic acidosis, renal dysfunction, hypothermia and 
septicaemia. During acute hyperammonemia severe encephalopathy developed after 
18.2±0.4 hours (n=6, mean±SEM). Other abnormalities found were cerebral edema and 
lactic acidosis. In both animal models comparable E.E.G. changes were observed (a 
decrease of mean dominant frequency and theta-activity, and an increase of delta-activity). 
However, these changes were not statistically significant, and non-specific as they also 
occurred in control-rabbits despite their clinical well-being. 
This study demonstrates in the rabbit the similarity between encephalopathy due to 
acute ischemic liver failure and that due to hyperanunonemia. An obsenred difference in 
hyperammonemia-induced encephalopathy was pronounced ataxia which did not occur 
during acute liver failure, whereas hypothermia. sepsis and renal failure occurred 
exclusively in acute liver failure. Our models appear satisfactory for the study of hepatic 
encephalopathy and ammonia toxicity. 
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INTRODUCTION 
For the study of the pathogenesis and the treatment of hepatic encephalopathy 
reliable animal models are needed. With the renewed interest in the role of 
hyperammonemia (1). there is also a need for reliable models of acute hyperammonemia. 
During development of acute liver failure anunonia increases gradually. Therefore in 
models of hyperammonemia, anunonia should also increase gradually. In most studies 
ammonia is administered in doses which lead rapidly to levels according to or higher than 
the peak levels encountered io acute liver failure (2-4). Sioce the effects of anunonia are 
related to degree and duration of hyperammonemia, the toxic effects of a bolus iojection 
of anunonia may differ from the effects of ammonia io liver failure (5). 
In our laboratory, rabbits with acute ischemic liver failure have been used in 
studies on hepatic encephalopathy (6, 7). 'fakiog both dose and exposure time into 
account, we developed an ammonia infusion model which simulates the plasma ammonia 
level found in rabbits with acute ischemic liver failure (8). We use this more 
pathophysiological model to study the mechanism of anunonia toxicity. 
Galactosamine induced acute liver failure in the rabbit is a well recognized model 
to study hepatic encephalopathy; it has been characterized for one type of inbred rabbit 
straio (9). However the time of development of hepatic encephalopathy is rather wide, 
ranging from 21 to 44 hours, and the hepatic necrosis is variable (9). Furthermore the 
hepatotoxic mechanism of galactosamine-induced hepatitis has not been completely 
elucidated and important toxic effects on other organs cannot be excluded (10,11). 
Therefore we favour a surgical model of acute liver failure. 
This paper describes in detail the clinical and biochemical features of acute 
ischemic liver failure and acute hyperarnmonemia in the rabbit. 
METHODS 
Animal models 
New Zealand white rabbits weighing 2-3 kg were used. Acute liver failure (ALF) 
was induced by two-stage liver devascularization (6). Under anesthesia laparotomy was 
performed: a ligature was placed around the hepatoduodenal ligament and guided through 
a plastic tube through the abdomioal wall to the subcutaneous layer of the left subcostal 
region, and a small-diameter (5 mm) side-to-side portacaval shunt was constructed. The 
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superior mesenteric artery was clamped to reduce splanchnic blood stasis. To correct 
acidosis after release of the vascular clamps 5 m.l 8.4% sodium bicarbonate were given 
intravenously. Postoperatively the rabbits were given 50 m.l I 0% glucose subcutaneously, 
followed by standard laboratory chow and water ad libitum. The second day after the 
operation, acute ischemic liver failure was induced by tightening the ligature around the 
hepatoduodenal ligament, after giving 50 mg amoxicillin intravenously. The rabbits were 
subsequently placed in a restraining box. To prevent hypoglycemia 10% glucose was 
given intravenously. starting at a volume of 3 ml/hr and which was adjusted according to 
the plasma glucose level when necessary. 
Acute hyperammonemia (AMM) was induced by prolonged intravenous 
anunonium acetate (NH,Ac) infusion (8). After insertion of a Venflon cannula (diameter 
0.8 mm, Viggo, Sweden) into an earvein, NH,Ac was infused at a constant volume of 6 
ml/hr, starting with an initial dose of 0.8 mmollkglhr, which was subsequently increased 
by 0.2 mmollkglhr every two hours. After 16 hours the dose remained constant. 
Control rabbits (C) received a sodium/potassium acetate (NaKAc) solution, which 
was infused -as far as the acetate concentration was concerned- as in the ~Ac 
experiments. 
Design of the study 
19 rabbits were studied: 7 with acute liver failure (ALF), 6 with acute 
hyperammonemia (AMM) and 6 controls (C). Before the start of the experiments and 
after the development of severe encephalopathy, clinical, neurophysiological and 
biochemical data were studied. A rabbit was considered to have severe encephalopathy 
when it layed in the cage, could not achieve the sitting position -even after stimulation-
and could not lift its head (encephalopathy stage B, as described earlier (7)). After 
completion of the measurements, the rabbits were sacrificed with pentobarbital l g/kg 
body weight (Euthesate, Gist Brocades, the Netherlands). Necropsy was performed to 
exclude gross morphological abnormalities and in case of acute liver failure to confirm 
tightening of the ligature. Brains were rapidly removed for determination of water 
contents. Rabbits were excluded from evaluation when survival did not exceed at least 6 
hours; in such cases death was considered to be due to postoperative complications. 
Clinical investigation 
Clinical investigation of the rabbits consisted of systematic neurological 
examination, performed hourly. Neurological signs studied were spontaneous activity, 
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body posture, righting reflex, muscle tone, hyperextension (opisthotonus), reaction to a 
painful stimulus, ataxia, nystagmus, pupillary and corneal reflexes, and the occurrence of 
convulsions. During the study the body temperature was measured (Philips Digital 
Thermometer, the Netherlands). 
Electroneurophysiological investigation 
One day before the experiment and under anesthesia three silver electrodes were 
implanted directly onto the dura for E.E.G. monitoring. Two were placed onto the right 
hemisphere, one anterior (3 mm) and one posterior (11 mm) to the sutura coronaria. The 
third electrode, the ground electrode, was placed onto the left hemisphere. The electrodes 
were fixed onto the skull with dental cement. Automated E.E.G. analysis (spectral 
analysis) was performed as follows (12). During 100 seconds, variations in the electric 
potentials between 0.53 and 70 cycles per second in the frontal-occipital lead were 
registered by an E.E.G.-apparatus (Van Gogh, the Netherlands). The data were fed in a 
personal computer (Olivetti M24, Italy). To avoid interference of high frequency energy, 
signals were filtered at 25.6 Hz. The power spectrum was constructed using Fast Fourier 
Transformation. Parameters calculated for the range 1-25.6 Hz were the mean dominant 
frequency (MDF) and the relative delta- and theta-activity (0.5-3.5 and 3.5-8.0 Hz 
respectively). 
Biochemical investigation 
After insertion of a Venflon cannula into an ear artery, arterial blood samples 
were taken at 0,1 and 2 hours, and every two hours thereafter for ammonia 
determination, using an enzymatic method (13). Blood glucose levels were measured 
hourly (Haemoglucotest, Boehringer, Germany). Before the start of the experiment and 
during encephalopathy stage B the blood was studied more extensively: arterial blood 
gasses and hemoglobin were determined using an acid-base laboratory (ABL 2, 
Radiometer Holland, the Netherlands). Blood chemistry was measured using an automatic 
analyser (CHEM 1, Technicon!Bayer, Germany): sodium, potassium, chloride, 
phosphate, urea, creatinin, total protein, albumin, total bilirubin, alkaline phosphatase, 
ALAT, ASAT, osmolarity and lactic acid. Immediately after sacrifice, blood was drawn 
for bacterial cultures. 
Cerebral edema 
The presence of brain edema was investigated by means of the dry weight method 
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(14,15). After removal of the brain, left and right cortex, hippocampus, cerebellum and 
brainstem were dissected. Samples of these brain regions were heated in an oven at 105 
'C until the weight remained constant. Thus the water contents could be calculated. 
Statistics 
The results are presented as mean±S.E.M. For statistical analysis the paired or 
unpaired Student's t test was used. Statistical significance denotes p < 0. 05. 
All experiments were approved by the ethical committee on animal experiments of 
the Erasmus Urdversity Rotterdam. 
RESULTS 
Each group of rabbits consisted of 6 animals. One rabbit with acute liver failure 
died after 4 hours and was excluded for further evaluation. The cause of death remained 
unknown; autopsy did not reveal gross abnormalities. 
Clinical data 
All rabbits studied developed encephalopathy. Encephalopathy stage B was reached 
after 10.2±1.9 hr in rabbits with acute liver failure and after 18.2±0.4 hr in rabbits with 
acute hyperammonentia (ALF vs. AMM p<0.05). Encephalopathy stage B from acute 
liver failure was characterized by complete loss of spontaneous activity, impaired body 
posture, absence of the righting reflex, marked hypotonia and unresponsiveness to a 
painful stimulus. Opisthotonus was observed in two rabbits with acute liver failure. 
Encephalopathy stage B from acute hyperammonemia was also characterized by loss of 
spontaneous activity and impaired body posture, but was preceded by pronounced ataxia. 
Absence of the righting reflex, hypotonia, opisthotonus and unresponsiveness to a painful 
stimulus were frequently observed. In one rabbit with acute hyperammonemia nystagmus 
occurred. Convulsions did not occur, neither during acute liver failure nor during acute 
hyperammonemia. Control rabbits were studied for 15 hours; they all behaved normally 
until the end of the experiment. See table !. 
Body temperature 
During the control studies and during ammonia infusion body temperature did not 
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Table I 
Neurological examination of rabbits with severe encephalopathy from acute hepatic failure and 
acute hyperarnmonemia. 
C (n=6) ALP (n=6) AMM (n=6) 
Neurological signs to tE to IE to tEB 
diminished activity 0 0 0 6 0 6 
hnpaired body posture 0 0 0 6 0 6 
disturbed righting reflex 0 0 0 6 0 4 
decreased muscle tone 0 0 0 6 0 3 
opisthotonus 0 0 0 2 0 3 
impaired reaction to pain 0 0 0 6 0 3 
ataxia 0 0 0 0 0 6 
nystagmus 0 0 0 0 0 1 
abnormal pupillary reflexes 0 0 0 0 0 0 
abnormal corneal reflexes 0 0 0 0 0 0 
convulsions 0 0 0 0 0 0 
C controls, ALP acute liver failure, AMM acute hyperarnmonemia 
to start of the experiment, tE encephalopathy stage B/ end of experiment. 
change significantly (C from 38.6±0.4 'Cat the beghnting to 39.5±0.3 'Cat the end of 
the study, and AMM from 39.5±0.3 'C to 39.2±0.6 'C). Duling acute liver failure there 
was a significant decrease of the body temperature: from 38.2±0.5 'C to 35.3±0.7 'C 
(p<0.05). 
Plasma ammonia levels 
During all experiments increases of arterial ammonia levels in the rabbits with 
acute liver failure and acute hyperarnmonemia, showed a shnilar pattern (table IT). At the 
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Table II 
Mean arterial ammonia levels (in l'mol/1) at the start of all experiments and during severe encephalopathy. 
Model to n t, n t, n t" n t. T. n 
c 22±7 6 30±7 6 21±2 6 13±5 6 37±13 15 6 
ALF 123± 12 * 6 
AMM 39±8 6 
299±36 6 596±203 4 349±58 # 2 
543±99 6 
679±89 10.2±1.9 6 
216±43 6 332±37 6 627±79 18.2±0.4 6 
C controls, ALF acute liver failure, AMM acute hyperammonemia, to start of the experiment, 
t4-t8-t12 after 4,8 and 12 hours respectively of acute liver failure/acute hyperammonemia, 
t. encephalopathy stage Blend of experiment, and T. time of development of encephalopathy 
stage Blend of experiment, in hours. 
Values are derived from six experiments and are expressed as mean±SEM. 
* p<0.05 ALF vs. C, and# p<0.05 ALF vs. AMM. 
Table ill 
Spectral analysis of the E. E.G. at the stan of the experiment and during severe 
encephalopathy stage B. 
Mean dominant frequency (Hz) 
Model 
c 
ALP 
AMM 
Delta-activity (%) 
Model 
c 
ALP 
AMM 
Theta-activity (%) 
Model 
c 
ALP 
AMM 
to 
4.5±0.2 
4.7±0.6 
5.3±0.3 
51.6±4.5 
57.2±7.4 
47.8±1.7 
to 
36.6±4.5 
27.8±4.0 
30.3±1.9 
"' 
3.6±0.4 
3.2±0.5 
3.6±0.4 * p<0.05 
64.7±8.4 
72.9±7.8 
70.0±3.1 * p<0.05 
tE 
28.2±7.4 
19.9±6.4 
24.4±2.8 
C controls, ALF acute liver failure, AMM acute hyperammonem.ia, 
to prior to induction of acute liver failure/acute hyperammonemia, 
tE encephalopathy stage Blend of experiment. 
Data are derived from 6 experiments and are expressed as mean±SEM. 
* p<0.05: statistical significance to vs. t •. 
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Table IV 
Arterial blood gasses, hemoglobin, lactic acid and glucose at the start of the experiments and during severe 
encephalopathy stage B. 
Units C-lo C-t. ALP-to 
pH 7.45±0.02 7.56±0.02* 7.45±0.01 
bicarbonate mmol/l 24.3±1.2 29.7±1.2* 22.3±0.6 
base excess mmol/l 0.9± 1.2 7.2±1.2* -0.8±0.5 
pC02 mmHg 34.9±0.8 33.4±1.0 32.4±1.3 
pO, mmHg 90.5±1.3 87.6±5.0 91.4±3.0 
0 2 saturation % 96.4±0.2 96.8±0.5 96.6±0.2 
hemoglobin mmol/1 14.5±0.4 12.3±0.3* 12.7±0.8 
lactic acid mmol/1 2.2±0.6 4.3±0.8 2.2±0.7 
glucose mmol/1 8.7±0.2 9.6±1.7 8.0±0.3 
C controls, ALP acute liver failure, AMM acute hyperammonemia. 
1o start of the experiment, t• encephalopathy stage Blend of experiment. 
Data are derived from 6 experiments and are expressed as mean±SEM. 
* p<0.05to vs. t •. 
ALP-t• AMM-Io 
7.34±0.09 7.45±0.02 
15.5±2.2 21.7±1.2 
-9.2±4.4 -1.1±1.4 
31.2±5.6 31.4±1.2 
98.3±21.8 93.4±2.9 
83.1 ± 13.8 96.7±0.3 
12.9±0.8 13.6±0.4 
14.2±2.4* 3.0±0.9 
7.9± 1.0 9.0±0.2 
AMM-t• 
7.24±0.05* 
9.2±1.0* 
-16.5±1.9* 
22.0±1.4* 
109.3±5.1* 
95.5±0.9 
11.9±0.5* 
16.5±3.6* 
11.9±0.9* 
start of the experiments ammonia levels were significantly higher in ALF-rabbits, when 
compared to AMM- or C-rabbits (p<0.05). After 12 hours, ammonia levels were 
significantly lower in ALF-rabbits when compared to AMM-rabbits (p<0.05). However, 
during encephalopathy stage B plasma ammonia levels were similar. 
Electroneurophysiological data 
The mean dominant frequency tended to decrease: ALF from 4.7 ±0.6 to 3.2±0.5 
Hz (p>0.05), AMM from 5.3±0.3 to 3.6±0.4 Hz (p<0.05) and C from 4.5±0.2 to 
3.6 ±0.4 Hz (p > 0.05)(table III). There was a concomitant increase of the delta-activity 
and decrease of the theta-activity (table III). Changes were significant for acute 
hyperammonemia only (p<0.05). It is important to note, that the changes occuring 
among the control rabbits were comparable to the changes in the ALF-and AMM-rabbits. 
Biochemical data 
All rabbits with acute ischemic liver failure had laboratory evidence of hepatic 
injury, indicated by elevated bilirubin and liver enzymes. Arterial blood gasses 
demonstrated normal oxygenation and ventilation in all animals stndied. At the start of 
theexperiments ALF-rabbits showed a tendency towards anemia, which can most likely be 
attributed to the laparotomy two days earlier. During infusion of NH4Ac and NaKAc, 
hemoglobin levels decreased significantly, probably due to dilution and blood sampling. 
Similar changes were observed for plasma albumin. All rabbits with severe 
encephalopathy had elevated plasma levels of lactic acid, resulting in acidosis. 
Hypoglycemia was not observed; hypoglycemia during acute liver failure was prevented 
by glucose infusion such that plasma glucose levels remained constant. During acute 
hyperammonemia mild hyperglycemia was observed. Renal function was diminished 
inALF-rabbits at the beginning of the experiment, which worsened after the induction of 
liver ischemia. In all rabbits stndied, plasma osmolality increased significantly, due to 
infusion of Na/K-acetate, ammonium acetate and increases of lactic acid. Urea levels 
increased during ammonia infusion resulting from increased urea formation from 
ammonia. Two rabbits with acute liver failure had positive blood cnltures (Staphylococcus 
epidermidis and Pseudomonas). After infusion of NEJ.Ac or NaKAc blood cnltures did 
not become positive. See tables IV and V. 
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Table V 
Renal function, electrolytes and albumin during acute liver failure and acute hyperannnonemia. 
Units C-to C-tn ALP-to ALF-t• AMM-to AMM-t8 
creatinine l'mol/1 63±5 79±16 178±76 321±65 111 ±20 131±20 
urea mmol/1 4.5±0.4 3.8±0.4 15.3±5.7 13.6±4.2 4.6±0.3 13.1 ±0.9* 
sodium mmol/1 138±0 150± 1 * 136±2 139±2 139±1 149±2* 
potassium mmol/1 4.9±0.2 3.7±0.0* 4.1±0.3# 5.5±0.8 4.7±0.1 5.3±0.5 
chloride mmol/1 104±2 114±1* 109±4 105±3 106±2 125±2* 
calcium mmol/1 3.6±0.1 2.7±0.1* 3.0±0.2# 2.7±0.2 3.6±0.1 2.8±0.1* 
phosphate mmol/1 1.8±0.1 1.6±0.1 2.3±0.5 3.8±0.2* 1.9±0.0 2.0±0.1 
osmolarity mosmol/1 292±3 303±3* 295±3 327±8* 288±2 326±6* 
albumin g/1 40.7±1.1 36.2±0.7* 35.2±1.2# 32.0±1.0 42.0±1.0 38.8±1.3 
C controls, ALP acute liver failure, AMM acute hyperammonemia. 
to start of the experiment, t, encephalopathy stage Blend of experiment. 
Data are derived from 6 experiments and are expressed as mean±SEM. 
* p<0.05 to vs. t., H p<0.05 vs. controls at t0• 
Brain edema 
Water contents of left and right brain structures did not reveal any significant 
differences; therefore, the means of left and rigbt are presented. Control animals had 
cortical water contents of 80.96±037%. During both acute liver failure and acute 
hyperammonemia, cortical water contents were increased but differences did not reach 
statistical significance (ALF 82.06±0.58% and AMM 8138±0.53%, p>0.05). During 
acute liver failure the water contents of hippocampus (ALF 82.77 ±0.49% vs. C 
81.19±0.22%) and cerebellum (ALF 80.46±0.26% vs. C 79.43±0.30%) were 
significantly elevated (p<0.05). During acute hyperammonemia brain water contents of 
hippocampus and cerebellum were also elevated, but differences did not reach statistical 
significance. In brain stem no significant changes were found. When we defmed the 
presence of cerebral edema or increased brain water contents as water contents above the 
upper lintit of the 95% confidence interval of the control values in at least 2 brain regions 
(two out of cortex, hippocampus, cerebellum and brainstem), then 4 out of 6 rabbits with 
acute liver failure and 4 out of 6 rabbits with acute hyperammonemia had increased brain 
water contents or cerebral edema. Brain water contents are summarized in table VI. 
DISCUSSION 
In this study we have evaluated our rabbit models of acute liver failure and acute 
hyperammonemia, for their similarities and dissimilarities, and to assess their suitability 
for the study of hepatic encephalopathy and ammonia toxicity. Acute liver failure was 
induced by two-stage liver devascularizatione; for technical reasons we favoured liver 
devascularization over hepatectomy. Acute hyperammonemia was induced by ammonia 
infusion such that the plasma ammonia levels found in acute liver failure were simulated. 
After laparotomy, rabbits appeared in good clinical shape, had moderate 
hyperanrmonernia indicating portacaval shunting, and showed signs of renal dysfunction 
which may be attributed to portocaval shunting (i.e. hepatorenal syndrome) but may also 
have been cansed by the devascularization procedure itself. All rabbits with acute liver 
failure and acute hyperammonemia developed severe encephalopathy within a 
narrowrange of time. Development was earlier in rabbits with acute liver failure, as we 
have also shown in previous studies (16,17). It is intriguing, that encephalopathy stage B 
was reached at similar plasma ammonia levels (table m. In both models, encephalopathy 
was characterized by diminished activity, impaired body posture and disturbed 
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Table VI 
Brain water contents of rabbits with severe encephalopathy from acute liver 
failure and acute hyperammonemia. 
c ALF AMM 
Cortex 80.96±0.37 82.06±0.58 81.38±0.53 
Hippocampus 81.19±0.22 82.77±0.49 * 81.68±0.46 
Cerebellum 79.43±0.30 80.46±0.26 * 80.28±0.25 
Brainstem 73.81±0.57 74.51±0.81 75.18±0.54 
C controls, ALF acute liver failure, AMM acute hyperammonemia. 
Values are derived from 6 experiments and are expressed as mean±SEM. 
* p<0.05 vs. controls. 
righting reflex; however in hyperammonemia pronounced ataxia preceded. We were not 
able to quantitate the encephalopathy in our rabbits with spectral analysis of the E.E.G., 
although this has been shown to be a sensitive technique to detect encephalopathy in rats 
(18). 
In addition to encephalopathy, there was development of other liver failure 
associated complications. Cerebral edema and lactic acidosis occurred in both models, 
whereas renal dysfunction, septicaemia and hypothermia occurred exclusively in acute 
liver failure. These complications, except for hypothermia, are also of importance in the 
human situation (19). 
In this study, we have demonstrated important similarities between acute 
liverfailure and acute hyperarnmonem.ia. However, important dissimilarities also became 
apparent. Major differences between the two models are a recent laparotomy and the 
presence of a portacaval shunt in rabbits with acute liver failure. These may have had an 
effect on the time of development of encephalopathy and the occurrence of other 
extrahepatic complications. Furthermore, hyperammonemia may exert different effects in 
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the presence of a portacaval shunt (20). 
Acute liver failure in rabbits has been studied by others. The clinical syndrome of 
galactosamine induced liver failure encompasses the development of encephalopathy, renal 
failure and cerebral edema (9,15). The ability of electroencephalography to measure the 
encephalopathy appeared poor with significant changes occurring only late in course (9). 
Studies on hepatectomized rabbits demonstrated the development of encephalopathy 
(diminished activity, ataxia, impaired body posture, decreased muscle tone), renal failure 
and hypothermia (21,22,23). Thus, acute liver failure in the rabbit appears to be rather 
uniform. Longterm ammonia infusion has not been performed earlier. 
Can we conclude that our models are suitable for the study of acute liver failure 
and ammonia toxicity? If acute liver failure is considered a syndrome resulting from the 
accumnlation of toxic substances no longer cleared by the liver, than our model of 
ischemic liver failure clearly appears suitable. However, when one considers toxic 
substances deriving from necrotic liver tissue to be of importance too, than this model has 
also a drawback in that there is minimal liver blood flow. In addition, a long-term 
ammonia infusion seems to be the method of choice to study the mechanism of ammonia 
toxicity in hepatic encephalopathy, which has also been noted by others (24). However, it 
is important to realize that our rabbits receiving an ammonia infusion were completely 
healthy, i.e. had not undergone recent laparotomy and did not have a portacaval shunt. 
In our opinion the animal models described here fulfill important requirements for 
satisfactory animal models to study encephalopathy from acute liver failure and acute 
hyperammonemia: the models are reproducible, encephalopathy develops in all rabbits 
within a narrow range of time and with similar plasma ammonia levels, frequent blood 
sampling is feasible, the models are not extremely costful, do not pose health hazards to 
the investigators and are approved by our university ethical committee on animal 
experiments. In addition, our models demonstrate important neurological and biochemical 
similarities between acute liver failure and acute hyperammonem.ia. Some of the 
differences between these models may be due to the fact that hyperarnmonemia may exert 
different effects in the presence of a portacaval shunt (20). Therefore development of a 
model of acute hyperarnmonemia in portacaval shunted rabbits would be of interest. 
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SUMMARY 
Hyperammonemia is thought to be important in the pathogenesis of hepatic 
encephalopathy. However, the mechanism leading to ammonia toxicity is still not known. 
Since the metabolism of the most important excitatory neurotransmitter glutamate is 
closely linked to that of ammonia, it has been postulated that hyperarmnonemia lowers the 
availability of the neurotransmitter glutamate. To study this hypothesis we used brain 
dialysis to measure glutamate levels in extracellular cerebral fluid from rabbits with acute 
ischemic liver failure or acute hyperarmnonemia. The basal glutamate concentration was 
found to be increased during both acute liver failure (start of experiments 4.9±1.7 
l'mol/1; end of experiments 9.5±2.ll'molll, n=6, difference p<0.05) and acute 
hyperarmnonemia (start of experiments 4.4±1.2 l'mol/1; end of experiments 7.3±1.8 
l'mol/1, n=7, difference p>0.05)(mean±SEM). Both the veratridine and the potassium-
evoked glutamate release were increased during acute liver failure but appeared normal 
during hyperanunonemia. It is concluded that during acute liver failure and acute 
hyperarmnonemia in the rabbit there is no decreased glutamate availability in the 
extracellular space of the cortical brain; contrary we found evidence for increased 
extracellular glutamate concentrations in cortical brain, which was more pronounced in 
acute liver failure. Experimental hepatic encephalopathy is not due to cerebral glutamate 
deficiency. 
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INTRODUCTION 
The pathogenesis of hepatic encephalopathy has not been completely elucidated 
yet. Currently, there is renewed interest in the role of hyperammonemia (1). The 
mechanism leading to ammonia toxicity is still not known. Hyperammonemia affects 
normal brain functioning in many ways; it may disturb basic cell functions (e.g. pH 
regulation and water and energy balance (2-4)), electrophysiology (5) and biochemical 
neurotransmission. In the present study we focussed on the effect of hyperammonemia on 
biochemical neurotransm.ission, in particular glutamate neurotransm.ission. 
The metabolism of glutamate, the most important excitatory neurotransmitter in 
the brain, is linked to that of ammonia (6). In neurons the neurotransmitter glutamate is 
produced from glutamine, through the enzymatic action of glutaminase. In vitro the 
activity of glutaminase, which is essential for the formation of glutamate, is inhibited by 
ammonia (7 -8). Thus it was assumed that ammonia decreases the amount of glutamate in 
the brain, which probably would have an effect on normal brain functioning. 
Subsequently, the amount of glutamate was shown to be decreased in autopsied brain 
tissue from patients as well as animals with hepatic encephalopathy (9-12). However, 
these were whole brain studies in which the total amount in all anatomical compartments 
(vascular, intracellular and extracellular) was assessed. The concentration of a 
neurotransmitter in the synaptic cleft, a part of the extracellular space, is probably the 
best reflection of neurotransmitter function. Since less than 1 % of the total amount of 
amino acid in the brain is found in the extracellular space, total brain measurements are 
not suitable for determining neurotransmitter function (13). The brain dialysis teclrnique 
has made the extracellular space more accessible for research (14-17). For brain dialysis a 
thin dialysis tube is implanted in a region of the brain of an animal. The tube is perfused 
with an electrolyte solution, and small molecules which pass througb the dialysis 
membrane can be measured in the dialysate. Before analyzing the glutamate 
concentrations in extracellular cerebral fluid, one has to distin,"Uish between glutamate 
derived from basal cell metabolism and that attributable to neurogenic events. Under 
normal conditions, the glutamate responsible for the "basal" concentration is derived 
mainly from the metabolic pool (18-19). After the addition of depolarizing agents, such as 
veratridine or potassium, "evoked" glutamate release from the neurotranSmitter pool is 
observed (19-20). 
In our laboratory we have rabbit models for both acute ischemic liver failure and 
acute hyperammonemia (21,22). In the latter model ammonia is infused such that the 
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plasma ammonia levels simulate these measured during acute ischemic liver failure (21). 
The aim of the present investigation was to determine in-vivo whether there is a 
hyperammonemia-induced deficit of the excitatory neurotransminer glutamate in the 
extracellular space of the brain during experimental hepatic encephalopathy. Therefore we 
studied the basal concentrations and evoked release of glutamate in our two rabbit 
models. 
METHODS· 
Animal models 
New Zealand white rabbits weighing 2-3 kg were used. Acute liver failure (ALF) 
was induced by a two-stage liver devascularization procedure (22). Under anesthesia a 
laparotomy was performed: a loose ligature was placed around the hepatoduodenal 
ligament and guided through a plastic tube through the abdominal wall, and a small-
diameter (5 mm) side-to-side portacaval shunt was constructed. On the first postoperative 
day a small dialysis tube was implanted in the cortex for brain dialysis, together with 3 
silver electrodes on the dura for E. E.G. registration. On the second postoperative day 
acute liver failure was induced by tightening the ligature around the hepatoduodenal 
ligament. The rabbits were subsequently placed in a restraining box. To prevent 
hypoglycemia 10% glucose was given intravenously. 
Acute hyperanunonemia (AMM) was induced by a prolonged intravenous 
anunoniurn acetate (NH.,Ac) infusion (21). NH.,Ac was infused at a constant rate of 6 
ml/hr, starting with an initial dose of 0.8 mmol/kglhr and increasing this dose by 0.2 
mmol/kg/hr every two hours. Control rabbits (C) received a sodium/potassium acetate 
(NaKAc) solution infused -as far as the acetate concentration was concerned- as in the 
NH.,Ac experiments. 
Brain dialysis 
Under anesthesia and after fixation of the head of the animal in a stereotaxic 
frame, the skull was exposed for bilateral trepanations 1 mm below the bregma. Then a 
dialysis tube (diameter 0.3 mm, Cordis Dow, Roden, the Netherlands) supported by a 
tungsten wire (Clark Tungsten Tubes TW 5.3, Reading, United Kingdom) was inserted 
through the trepanation holes into the cerebral cortex with the aid of a stereotaxic 
micromanipulator. The dialysis tube was fixed with glue in polyethylene tubing 
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(0.28x0.61 mm, Rubber, Hilversum, the Netherlands). Brain dialysis was performed 
between 24-48 hours after implantation (23-24). One end of the dialysis tube was 
connected to a syringe pump (Harvard Syringe Infusion Pump 22, U.S.A.) and perfused 
with Krebs-Ringer's solution (composition in mmol/1: NaCI 122; KCI 3; MgS04 1.2; 
KH2PO, 0.4; NaHC03 25; CaCI2 1.2; pH 7.35-7.45; 2.5 1'1/min) (figure 1). To check the 
position of the dialysis tube in the cortex the brains of all rabbits were dissected. 
Design of the study 
Three sets of experiments were performed. The basal concentrations of glutamate 
were studied in the first set of 19 expetiments (6 ALF, 7 AMM, 6 C), the veratridine-
evoked glutamate release in the second set of 22 expetiments (7 ALF, 7 AMM, 8 C) and 
the potassium-evoked glutamate release in the third set of 18 expetiments (6 ALF, 6 
AMM, 6C). 
AU experiments started with flushing for one hour to achieve equilibration. During 
the basal studies samples were collected in one-hour fractions. After the first one-hour 
period, acute liver failure was induced or the NH4Ac or NaKAc infusion was started. 
Brain dialysis was performed continuously until death from acute liver failure or acute 
hyperarnmonemia. Control studies were performed for 12 hours. 
The studies of the veratridine and potassimn-evoked release of glutamate started 
with a 60-minute period to determine the basal concentration. Then, veratridine (100 
l'mol/1, Sigma, U.S.A.) or potassiutn (KCl 100 mmol/1, NaCl concentration was reduced 
to 25 mmol/1 to maintain iso-osmo!arity) was added to the perfusate for 10 minutes with 
the aid of the liquid switch (Carnegie Medical, Stockholm, Sweden), and the dialysate 
was collected during 6 consecutive periods of 10 minutes. These 60-minute and 6 10-
minute samples reflect glutamate release prior to the induction of acute liver failure or 
acute hyperammonemia. Ten hours after the induction of acute liver failure or the start of 
the NH.,Ac or NaKAc infusion, brain dialysis was again performed: one hour to achieve 
equilibration, one hour for measurement of the basal concentration and one hour (6x10) 
for measurement of the veratridine or potassium-evoked release. 
Concentrations of glutamine and glutamate are presented as concentrations in the 
dialysate (!'moll!) or as the release into the dialysate (pmol/10 minutes). 
Laboratory measurements 
The amounts of glutamate and glutamine in the dialysates were quantified by high 
performance liquid chromatography on a liquid chromatograph (Hewlett Packard 1084B, 
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Figure 1 
Schematic representation of brain dialysis. A thin dialysis tube is placed in the cerebral cortex (C) 
of the rabbit; the tube is connected to the syringe pump (P). The tube is perfused with Krebs-
Ringer's solution, 2.5 ,ul/min. The "liquid switch" (L) ensures rapid changes to different 
perfusates. S skull, F cerebrospinal fluid. 
Palo Alto, California, U.S.A.), usiog a modification of the procedure described by Kraak 
et al. (25). Samples of 25 JLl were iojected onto a 150x4.6 mm Hypersil ODS 5 I'm 
column (Chrompack, Middelburg, the Netherlands). The mobile phase consisted of 4 mM 
NaH2P04 , 0.1% (w/v) sodium dodecylsulfate and 0.3% (w/v) tertiary amylalcohol, pH 
2.80. A flow rate of 0.8 ml/mio was used and the column was operated at 30"C. 
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Detection of the amino acids was accomplished after derivatization with 
orthophthaldialdehyde (26). 
Arterial blood samples were taken from all rabbits at 0,1 and 2 hours and then 
every two hours for ammonia determinations (27). Blood glucose levels were measured 
hourly (Haemoglucotest, Boehringer, Germany). To prevent hypoglycemia in ALF rabbits 
the rate of the glucose infusion was adjusted to blood glucose levels. 
Clinical signs of encephalopathy 
During the study rabbits were restrained. Clinical signs could not therefore be 
evaluated during brain dialysis. However, after the studies of the veratridine and 
potassium-evoked release were completed, the rabbits were evaluated clinically. Clinical 
signs studied were spontaneous activity, righting reflex, ataxia, pupillary reflex and 
reaction to a painful stimulus. 
Spectral analysis of the E.E. G. 
During implantation of the dialysis tube 3 silver electrodes were also fixed directly 
on the dura for E.E.G. measurements. Two were placed on the right hemisphere, one 
anterior (3 mm) and one posterior (11 mm) to the sutura coronalis. The ground electrode 
was placed on the left hemisphere. The electrodes together with the polyethylene tube, 
containing the dialysis tube, were fixed onto the skull with dental cement. Automated 
E.E.G. analysis (specttal analysis)(28) was performed hourly during the determination of 
the basal glutamate concentrations. During the studies of the evoked glutamate release 
specttal analysis was performed just before each stimulus. 
Statistics 
The results are presented as the mean ± S.E.M. For statistical analysis the paired 
or unpaired Student's t test was used. Statistical significance was set at p<0.05. 
All experiments were approved by the ethical committee on animal experiments of 
the Erasmus University Rotterdam. 
RESULTS 
Survival time 
During the first set of experiments all animals with acute liver failure or acute 
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hyperammonemia died after 11±2 and 14±1 hours, respectively. Control studies 
(NaKAc) were performed for 12 hours: one unexplainable death occurred after 11 hours. 
According to the protocol for the study of evoked release, the rabbits had to survive for at 
least 12 hours after the first stimulus. Thus, in the veratridine experiments the data on 7 
out of 9 ALF rabbits, 7 out of 9 AMM rabbits and 8 out of 8 controls could be evaluated. 
In the potassium experiments these numbers were 6 out of 10, 6 out of 7 and 6 out of 6, 
respectively. 
Plasma ammonia levels 
The increases in arterial ammonia levels in rabbits with acute liver failure and 
acute hyperammonemia were shnilar. At the start ammonia levels tended to be higher in 
ALF rabbits (93±lll'molll), due to their portacaval shunt, than in AMM rabbits (31±10 
l'ffiOl/1) or controls (25±10 l'mol/1). During the experiments the mean arterial ammonia 
levels among rabbits receiving an ammonia infusion were not significantly different from 
those among rabbits with acute liver failure [p >0.05]. One hour before the death of the 
rabbits used in the basal glutamate studies -a time when all rabbits were assumed to have 
shnilar degrees of encephalopathy- plasma ammonia levels also did not differ significantly 
[p>0.05] between rabbits with acute liver failure (456±1221'molll) and rabbits with 
acute hyperammonemia (690±86 l'ffiOl/1). The plasma ammonia levels in the second and 
third sets were comparable to those of the first set. Plasma ammonia levels are 
summarized in figure 2 and table I. 
Plasma glucose levels 
None of the rabbits developed hypoglycemia. During acute liver failure plasma 
glucose levels did not change significantly (at the start: 8.4±0.4 mmol; one hour before 
death: 7.1±0.6 mmol/1 [p>0.05]), whereas the plasma glucose levels during ammonia 
infusion increased from 7.5±0.7 mmol/1 to 19.0±2.3 mmol/1 [p<0.05]. During control 
studies plasma glucose levels did not change (at the start: 8.3±0.5 mmol/1; at the end: 
8.9±0.9 mmol/1 [p>0.05]). 
Spectral analysis of the E.E.G. 
Spectral analysis of the E.E.G. showed a significant decrease in the mean 
domirumt frequency (MDF) during development of encephalopathy as a result of acute 
liver failure (at the start: 4.3±0.3 Hz; one hour before death: 3.2±0.5 Hz, p<0.05) as 
well as acute hyperammonemia (at the start: 5.8±0.4 Hz; one hour before death: 
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Time course of plasma ammonia levels in rabbits with acute ischemic liver failure or acute 
hyperammonemia and control rabbits. Values are the mean±SEM. 
ALF: n= 19, dotted line; AMM: n=20, interrupted line; C: n=20, continuous line. 
3.1 ±0.3 Hz, p<0.05)). Probably the portacaval shunt explains why ALP rabbits tended 
to have a lower MDP at the beginning of the experiment than AMM rabbits. One hour 
before the death of the rabbits used to study basal concentrations, the severity of the 
encephalopathy (as indicated by the MDP) in ALP rabbits was similar to that in AMM 
rabbits. During the NaKAc infusion the MDP did not change (table I). 
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TABLE I 
Plasma ammonia, mean dominant frequency of the E.E.G. and the basal extracellular concentrations of glutamine and glutamate. 
Study Model (n) 
B ALP (6) 
AMM (7) 
c (6) 
v ALP (7) 
AMM (7) 
c (8) 
K ALP (6) 
AMM (6) 
c (6) 
MDP ofEEG 
(Hz) 
t, l12/leru 
4.3±0.3' 3.2±0.51 
5.8±0.4 3.)±0.3' 
5.4±0.4 5.3±0.3 
5.0±0.5 3.0±0.41 
5.2±0.6 4.6±0.4 
5.3±0.4 5.3±0.3 
4.7±0.2 3.0±0.3' 
5.4±0.2 4.0±0.4 
5.2±0.4 4.7±0.2 
Plasma ammonia 
(pmol/1) 
t, l12/tend 
93±11' 456± 1221 
31± 10 690±861 
25±10 39±10 
74±21 373±47' 
19±4 465±521 
28±5 29±14 
64±18 396±24' 
20±8 611 ±791 
24±3 29±8 
Extracellular glutamine 
(pmol/1) 
t, t12/tml 
147± 18 469±96' 
104± 19 313±391 
99±6 78±9 
158±35 374±34' 
99±12 243±211 
86±5 77±3 
117±30 354±641 
93±11 296±34' 
89±24 59±7 
Extracellular glutamate 
(pmol/1) 
t, 112/tend 
4.9± 1.7 9.5±2.1' 
4.4± 1.2 7.3± 1.8 
3.9±1.2 3.4±1.1 
3.3±0.8 8.4±3.3 
4.1±0.8 5.5±0.9 
3.4±0.7 3.4±0.5 
4.0±0.4 7.2±0.9 
2.8±0.6 3.6±0.7 
1.9±0.3 1.8±0.2 
Clinical signs of encephalopathy 
After twelve hours of liver ischemia all 13 rabbits (7 veratridine and 6 potassium) 
showed signs of encephalopathy: there was no spontaneous activity, the rabbits were 
unable to sit or lift their heads, and the righting reflex was absent. Other abnormalities 
noted were: severe ataxia (3x), absence of pupillary reflexes (2x) and diminisbed reaction 
to a painful stimulus (4x). After twelve hours of ammonia infusion signs of 
encephalopathy could be detected in 7 out of 13 rabbits (7 veratridine and 6 potassium). 
These rabbits showed loss of spontaneous activity and absence of the righting reflex. Two 
were also unable to sit and lift their heads, and ataxia was observed in 3 rabbits. 
Convulsions were not observed. In the control group (8 veratridine and 6 potassium) two 
rabbits exhibited absence of spontaneous activity and loss of the righting reflex. 
Glutamine level in cortical brain dialysate (Table I and i'"Iglll'e 3) 
During the basal studies the glutamine level in cortical brain dialysate rose 
significantly in parallel with plasma ammonia in rabbits with acute liver failure as well as 
those with acute hyperammonemia. During acute liver failure the concentration of 
glutamine in the dialysate increased from 147±18 fLill.Ol/1 to 469±96 ,umol/1 [p<0.05], 
during hyperanunonemia from 104±19 ,umol/1 to 313±39 ,umol/1 [p<0.05]. The 
differences between the two experimental groups did not reach statistical significance at 
any time [p>0.05]. The contrOls exhibited no significant changes (99±6 ,umol/1 at the 
begimting and 78±9 fLill.OI/1 at the end of the experiments [p>0.05]). 
Table I 
B: basal studies, V: studies of veratridine-evoked release and K: studies of potassium-
evoked release. 
ALF acute liver failure, AMM acute hyperammonemia, C controls, n number of 
experiments. 
to start of the experiment or prior to induction of acute liver failure/acute 
hyperanunonemia, t12 12 hours after induction of acute liver failure/acute 
hyperammonemia, and r..,, one hour before death in basal studies. 
Values are the mean±SEM. • p<0.05 vs. controls,' p<0.05 both vs. to and controls. 
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Figure 3 
Changes in basal glutamine levels in cortical brain dialysate of rabbits with acute ischenllc liver 
failure or acute hyperammonemia and control rabbits. Values are the mean±SEM. 
ALF: n=6. dotted line; AMM: n=7, interrupted line; C: n=6, continuous line. 
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Figure 4 
Changes in basal glutamate levels in cortical brain dialysate of rabbits with acute ischemic liver 
failure or acute hyperammonemia and control rabbits. Values are the mean±SEM. 
ALF: n=6, dotted line; AMM: n=7, interrupted line; C: n=6, continuous line. 
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Upon veratridine and potassium stimulation the glutamine concentration in the 
cortical brain dialysate decreased, indicating glutamine uptake by the nervous tissue 
surrounding the dialysis tube. Glutamine uptake was similar in the three expetimental 
groups studied; twelve hours of ischemic liver failure or hyperammonemia did not induce 
significant changes. 
Basal glutamate level in cortical brain dialysate (table I and figure 4) 
In ALF rabbits the glutamate concentration in the dialysate increased from 4.9±1.7 
ELmo! to 9.5±2.1/Lmol/l [p<0.05], in AMM rabbits from 4.4±1.2/Lmol/1 to 7.3±1.8 
!LffiOl/1 [p>0.05]. Control rabbits exhibited no changes (beginning with 3.9±1.2/Lmol/1 
and ending with 3.4±1.1/Lmol/1). 
Veratridine-evoked glutamate release in cortical brain dialysate (figure 5, upper 
panel) 
In the control group the first addition of veratridine to the perfusate for 10 minutes 
doubled the glutamate concentration in the dialysate, with a maximal increase in the 
glutamate concentration of 4.8±0.7 /Lmol/1. After 12 hours of NaKAc infusion this effect 
had decreased significantly to 3.0±0.4/Lmol/1 [p<0.05]. Similar results were obtained 
for the AMM rabbits, although the differences were not statistically significant: maximal 
increase in the concentration prior to ammonia infusion was 5.2±1.0 /Lmol/1 versus 
3.7±0.8/Lmolll after 12 hours of ammonia infusion [p>0.05]. In ALF rabbits the 
veratridine-evoked glutamate release did not change: before induction the maximal evoked 
increase in the concentration was 6.2±!.3 !LffiOI/1, and 12 hours after induction of acute 
liver failure it was 6.2±2.0 /Lmol/1. The evoked glutamate release was higher in ALF 
rabbits; after 12 hours of acute liver ischemia the differences were significant, when 
Figure 5 
Veratridine-evoked glutamate release (upper panel) and potassium-evoked glutamate release 
(lower panel) in control rabbits and in rabbits with acute hyperammonemia or acute ischemic 
liver failure. Values represent release in pmol/10 minutes. Values are the mean±SEM. 
Veratridine: C n~8, AMM n~7, ALF n~7. Potassium: C n~6, AMM n~6, ALF n~6. 
Continuous line represents stimulation prior to induction of acute liver failure/acute 
hyperammonemia; dotted line represents stimulation 12 hours after induction of acute liver 
failure/acute hyperammonemia. 
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compared with rabbits exposed to NH.,Ac or NaKAc [p<0.05]. 
Potassium-evoked glutamate release in cortical brain dialysate (figure 5, lower panel) 
In the controls the frrst addition of potassium to the perfusate for 10 minutes 
induced a maximal increase in the glutamate concentration of 2.4±0.9 JLIDOI/1. After 12 
hours of NaKAc infusion the evoked glutamate release bad not changed significantly 
(3.2±0.9 l'mol/1). The glutamate release in response to the frrst addition of potassium 
was somewhat less in AMM rabbits (1.8±0.5 JLIDOlll), although these differences were 
not statistically significant. The potassium-evoked glutamate release did not change after 
12 hours of NH.,Ac infusion (2.3 ±0.3 JLID0!/1). Before the induction of acute liver failure, 
the evoked glutamate release was not significantly different from that in control rabbits 
(3.12±0.24 JLffiOl/1). After 12 hours of acute liver failure the maximal response had not 
changed significantly (4.1±0.9JLm0!/1, [p>0.05]); however, the levels usually did not 
return to baseline values. 
DISCUSSION 
In this study, based on in-vivo brain dialysis of rabbits with acnte ischemic liver 
failure or acute hyperammonemia, we found an increased basal concentration of the 
excitatory neurotransmitter glutamate in the cortical brain dialysate. The veratridine and 
potassium-evoked glutamate release appeared to be unchanged in rabbits with acute 
hyperammonemia, when compared with controls, but was increased in rabbits with acute 
liver failure. The veratridine-evoked release of glutamate prior to the induction of acute 
liver failure (i.e. after portosystemic shunting for 48 hours) tended to be higher than in 
control rabbits. After 12 hours of acute liver failure the release appeared to be 
unchanged; however, when compared to control rabbits in which the veratridine evoked 
release was decreased after 12 hours, we probably demonstrated an increase. After 12 
hours of acute liver failure the maximal potassium-evoked glutamate release had not 
changed, but the levels usually did not return to baseline values. However, in interpreting 
microdialysis data it is important to note that the concentration of amino acids measured 
in the dialysate are a reflection of the total actual extracellular concentrations. It is 
unknown how changes of an amino acid in the dialysate correspond to fluctuations of the 
concentration in the synaptic cleft. 
In the studies of the basal glutamate concentration rabbits with both acute liver 
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failure and acute hyperammonemia developed encephalopathy followed by death, which 
was accompanied by comparable elevations of the plasma ammonia levels. These findings 
demonstrate the potential of ammonia to induce encephalopathy and death. The fmdings 
of increased basal extracellular glutamate levels in rabbits with acute liver failure and 
with acute hyperarnmonemia suggest that hyperammonemia might have caused this 
increase. The more pronounced increase in basal glutamate levels and the increased 
evoked glutamate release in rabbits with acute liver failure, indicate that other factors may 
contribute to the increased extracellular glutamate level in acute liver failure. However, it 
should be noted that the reaction to hyperammonemia in rabbits with acute liver failure 
may have been different from that in normal rabbits, due to the existence of a portacaval 
shunt (29); furthermore, in the studies of the evoked release the degree of encephalopathy 
was less for rabbits with hyperamm.onemia than for those with acute liver failure. 
Other studies based on brain dialysis have been reported: rabbits with 
galactosamine-induced liver failure as well as rats with a portacaval shunt were also found 
to have increased basal glutamate levels, whereas rats with a portacaval shunt exhibited a 
normal potassium-evoked release of glutamate (14-17). Most other studies on hepatic 
encephalopathy and hyperammonemia have demonstrated decreased glutamate levels. 
Studies of hippocampal slices and isolated nerves demonstrated decreased glutamate 
availability during hyperammonemia (30-32). Postmortem studies in rats and in patients, 
and a recent study using in vivo nuclear magnetic resonance spectroscopy in rats also 
indicated decreased glutamate levels (9-12). However, in these studies total brain 
concentrations were measured and since less than 1 % of the total amount of amino acid is 
located in the extracellular space, total brain measurements are not suitable for 
determining amino acid neurotransmitter function (13). A study based on the cortical cup 
technique reported an ammonia-induced increase in extracellular basal glutamate 
concentrations with a concomitant decrease in the total brain glutamate content (33), 
which emphasizes the importance of measuring extracellular concentrations. 
Thus during experimental encephalopathy due to acute liver failure or acute 
hyperammonemia there is likely to be an increase in the glutamate concentration in the 
extracellular space. It is still not clear whether this increase stems from the metabolic or 
neurotransmitter pool of glutamate. The results of our studies on the evoked release 
during acute liver failure suggest the neurotransmitter pool; changes in the potassium-
evoked release point to impaired re-uptake. since the glutamate concentrations tended to 
remain elevated whereas the initial responses were similar. Ammonia-induced impaired 
re-uptake has been demonstrated in-vitro (32). However, although the evoked release of 
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glutamate comes mainly from the neurotransmitter pool under normal conditions, a 
contribution from the glial comparttnent cannot be excluded here since glial cells exhibit 
many abnormalities during hyperammonentia and hepatic failure (34). 
How can increased extracellular brain glutamate levels give rise to hepatic 
encephalopathy, or is this just an epiphenomenon? After release into the synaptic cleft, 
glutamate binds to its receptors. An increased glutamate concentration will give rise to 
prolonged and/ or increased exposure of these receptors to glutamate. This could have two 
effects: it could lead to compensatory down-regulation and/or there could be a direct toxic 
effect. 
It appears logical to assume that increased exposure of receptors to glutamate 
induces down-regulation (35). Some studies on glutamate receptors in hepatic 
encephalopathy indicate a decreased number of receptors (36-40), whereas others could 
not fmd any changes (41). 
The other effect of increased glutamate exposure may be a direct toxic effect. 
There is evidence indicating that prolonged glutamate exposure is deleterious to the brain 
(42). In-vitro experiments have demonstrated that increased glutamate levels are toxic to 
both neurons and glial cells (43-45). Most toxic effects of glutamate are thought to result 
from a prolonged depolarizing action of glutamate at its postsynaptic receptor sites ( 43-
45). This action is assumed to cause changes in membrane permeability which lead to 
impaired ion homeostasis (4344). 
Increased glutamate concentrations in the cerebrospinal fluid of patients with 
hepatic encephalopathy suggest that increased glutamate exposure also occurs clinically 
(46-48). The increased extracellular glutamate levels in our animal models of hepatic 
encephalopathy and hyperammonemia, together with the knowledge that glutamate 
toxicity occurs in other diseases, indicate that glutamate metabolism and toxicity should 
receive further attention from investigators engaged in the field of hepatic encephalopathy. 
In conclusion, during encephalopathy due to acute ischemic liver failure or acute 
hyperammonem.ia in the rabbit there is no deficit of the excitatory neurotransmitter 
glutamate. On the contrary, we found evidence for increased glutamate availability during 
hyperammonentia and hepatic encephalopathy. 
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SUMMARY 
Binding of the ligand fH]MK-801 to the MK-801 binding site of the N-methyi-D-
aspartate (NMDA) receptor population on brain homogenates in rabbits was studied 
dnring experimental encephalopathy from acute liver failnre and from acute 
hyperammonemia in the rabbit. Homogenates were prepared from brain cortex, 
hippocampus and striatum. Hepatic encephalopathy was induced by a two-stage liver 
devascularization procedure and acute hyperammonemia by a prolonged ammonium 
acetate infusion; rabbits receiving a sodium/potassium acetate infusion served as controls. 
In these animal models extracellular brain glutamate levels are known to be elevated. 
However no significant alterations in the number nor the affinity of the MK-801 binding 
sites of the NMDA receptors were found dnring acute liver failnre and acute 
hyperammonemia. These findings suggest that the NMDA receptor population remains 
unaltered in experimental encephalopathy from acute liver failnre and acute 
hyperammonemia, despite alterations in extracellular brain glutamate levels. 
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INTRODUCTION 
Hepatic encephalopathy is a neuropsychiatric syndrome caused by serious liver 
disease. Hyperammonemia is thought to be an important causative factor since plasma 
ammonia levels often correlate with the degree of encephalopathy (1), administration of 
ammonium-salts to patients with chronic liver disease provokes encephalopathy (2) and 
lowering of plasma ammonia by lactulose therapy often diminishes encephalopathy (3). 
Furthermore proliferation of astrocytes -the morphological substrate of chronic hepatic 
encephalopathy- is also found in patients with the congenital hyperammonemia syndromes 
(4). However. the exact mechanism how hyperammonemia contributes to the syndrome of 
hepatic encephalopathy remains to be elucidated. 
One of the current opinions with regard to the pathogenesis of hepatic 
encephalopathy is a dysbalance between neuro-inhibition and neuro-excitation (5). Several 
groups have proposed that neuro-inhibition via GABA or endogenous benzodiazepines is 
enhanced; we are investigating whether excitatory neurotransmission -especially glutamate 
neurotransmission- is diminished during hepatic encephalopathy. A large portion of 
central mammalian neurons use the amino acid glutamate as an excitatory neurotrans-
mitter (6), and the metabolism of glutamate is related closely to ammonia metabolism (7). 
In vitro and in vivo experiments have shown that both liver failure and hyperammonemia 
may alter brain glutamate homeostasis. Whole brain glutamate contents were found to be 
diminished during hepatic encephalopathy or hyperammonemia in patients as well as 
animals (8-12). Recently, using in vivo brain dialysis, we have demonstrated increased 
extracellular glutamate levels in the brains of rabbits developing encephalopathy from 
acute ischemic liver failure or acute hyperammonemia (13). The fmding of increased 
extracellular glutamate concentrations indicates increased glutamate availability in the 
synaptic cleft, i.e. increased glutamate exposure at the receptor level, during hepatic 
encephalopathy and hyperammonemia. Increased glutamate concentrations in the 
cerebrospinal fluid of patients with hepatic encephalopathy suggest that increased 
glutamate exposure also occurs clinically (14-16). To explain the paradoxical observation 
of increased excitatory neurotransmitter molecules in a state of neuroinhibition, the 
following hypothesis was constructed. Initially, increased glutamate levels lead to 
increased excitation; thereafter prolonged activation of glutamate receptors leads to a 
compensatory down~regulation (17), which in turn impairs glutamate neurotransmission. 
To determine whether the encephalopathy observed in our animal models is 
associated with changes in the glutamate receptors, we performed binding studies in 
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brains from rabbits developing encephalopathy from acute liver failure or acute 
hyperammonemia. As the N-methyl-D-aspartate (NMDA) receptor is the best 
characterized of the acidic amino acid receptor subtypes (18), we measured the binding of 
fH]MK-801 -a specific ligand of the NMDA receptor- to homogenates prepared from 
different regions from the brains of normal rabbits and rabbits with encephalopathy due to 
acute ischemic liver failure or acute hyperammonemia. 
METHODS 
Animals 
18 (3 groups of 6) New Zealand white rabbits weighing 2-3 kg were used. 
Animal models 
Acute liver failure was induced by a two-stage liver devascularization procedure as 
described earlier (19,20). Uuder anesthesia a laparotomy was performed: a loose ligature 
was placed around the hepatoduodenalligament and guided through a plastic tube through 
the abdominal wall to the subcutaneous layer of the left subcostal region, and a small-
diameter (5 mm) side-to-side portacaval shunt was constructed. During this procedure the 
superior mesenteric artery was clamped to reduce splanchnic blood stasis. To correct 
acidosis after release of the vascular clamps 5 ml 8.4% sodium bicarbonate were given 
intravenously. Postoperatively the rabbits were given 50 ml 10% glucose subcutaneously, 
followed by standard laboratory chow and water ad libitum. The second day after the 
operation acute ischemic liver failure was induced by tightening the loose ligature around 
the hepatoduodenal ligament after giving 50 mg amoxicillin intravenously. The rabbits 
were subsequently placed in a restraining box. To prevent hypoglycemia 10% glucose 
was given intravenously, starting at a rate of 3 mlfhr and which was adjusted according to 
the plasma glucose level when necessary. 
Acute hyperammonemia was induced by a prolonged intravenous ammonium-
acetate (NII.Ac) infusion as described earlier (20). After insertion of a Venflon cannula 
(diameter 0.8 mm, Viggo, Helsingborg, Sweden) into an earvein, NH.,Ac was infused at a 
constant rate of 6 mlfhr, starting with an initial dose of 0.8 mmol/kglhr, which was 
subsequently increased by 0.2 mmol/kg/hr every two hours. 
Control rabbits received a sodium/potassium acetate (NaKAc) solution, which was 
infused -as far as the acetate concentration was concerned- as in the NH.,Ac experiments. 
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Laboratory measurements 
Arterial blood samples were taken from all rabbits studied at 0,1 and 2 hours, and 
every two hours thereafter for ammonia determination, using an enzymatic method (21). 
Blood glucose levels were measured hourly (Haemoglucotest, Boehrioger, Germany). 
Clinical signs of encephalopathy 
During study all rabbits were kept in a resrraining box. However, at regolar time-
intervals the rabbits were put into a large cage for clinical evaluation. Clinical signs 
studied were spontaneous activity, body posture, righting reflex, presence of ataxia and 
reaction to a painful stimulus. In most rabbits with acute hepatic encephalopathy due to 
ischemic liver cell necrosis two stages of hepatic encephalopathy are easily recognizable 
(22). Stage A is characterized by a disturbed righting reflex: the animal will not get up 
innnediately when placed on its side. At stage B the rabbit lies in the cage and cannot 
achieve the sitting position, even after stimulation, and usually cannot lift its head. All 
rabbits with ischemic liver cell necrosis and all rabbits receiving NH.,Ac were sacrificed 
during encephalopathy stage B. The rabbits receiving NaKAc were sacrificed at the same 
time as the rabbits receiving NH.,Ac. All animals were sacrificed by decapitation. 
['H]MK-801 binding to the MK-801 binding site of the NMDA receptor 
Within 10 minutes after decapitation the brain was removed and hippocampus, 
frontal cortex and striatum were dissected. Tissue samples were sealed in vacuum plastic 
bags and stored at -70'C umil further analysis. The binding of ['H]MK-801 to the MK-
801 binding site of the NMDA receptor was studied as described earlier (23-25). Rabbit 
brain tissue was homogenized in about 50 volumes of buffer with a glass-teflon 
homogenizer (at 2'C; 5 mM Tris-HCI buffer, pH7.4; PotterS. Braun, FRG). The 
homogenate was pelleted (15000 x ~· 20 min), resuspended by vortexing and pelleted 
again. Then the homogenate was pelleted ( 40000 x ~· 20 min) and resuspended 4 times in 
buffer. The protein concentration was measured in the fiual homogenate with bovine 
gamma-globulin as standard (26). Binding experiments were carried out at 21'C in plastic 
microtitre plates in a total volume of 0.22 ml. First, in hippocampus, cerebral cortex and 
striatum a one-point-binding assay was performed for which the incubation medium 
consisted of 0.22 m15 mM Tris-HCL (pH 7.4) containing 3 nM ['H]MK-801, 5 I'M L-
glutamate, 5 !<M L-glycine, 10 !<M MgCI2• Second, in the cerebral cortex saturation 
studies were performed for which 0.2-80 nM ['H]MK-801 was used. After incubation for 
22 hours bound ligand was separated from free ligand by rapid filtration through 
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Whatman GF IB filters with a Titertek cell harvester followed by a 10 second wash with 
cold assay buffer (4'C)(27). The filters were transferred into plastic vials, 5 m1 of a to-
luene-based scintillation cocktail was added (Rotiszint 22) and they were monitored for 
tritium in a Beckman LS 1801 counter at about 54% efficiency. Non-specific binding was 
defmed as that not displaced by 100 pM of unlabelled MK-801. Final estimates of binding 
parameters were determined with a computerized, non-linear, least squares regression 
analysis (28). 
Because experimental acute liver failure and acute hyperarnmonemia are known to 
increase brain water content by about ca. 2% (29,30), calculation was based on pmol/mg 
protein nnit. Such calculation is practically independent of the presence of cerebral 
edema, as opposed to a calculation based on tissue weight. 
Necropsy 
After sacrifice of the animal necropsy was performed to exclude gross pathological 
abnormalities. In the animals with acute ischemic liver cell necrosis the liver was 
examined carefully to confirm tightening of the ligature. 
Statistics 
All results are presented as mean±S.E.M. For statistical analysis the unpaired 
Student's t test when comparing two groups and the Stndent-Newman-Keuls test when 
comparing three groups were applied. Statistical significance denotes p<0.05. 
All experiments were approved by the Ethical Committee on Animal Research of 
the Erasmus University Rotterdam. 
RESULTS 
Clinical signs of encephalopathy 
Encephalopathy from acute liver failure was characterized by complete loss of 
spontaneous activity, impaired body posture, absence of the righting reflex, decreased 
muscle tone and a diminished reaction to a painful stimulus. Rabbits with encephalopathy 
from acute hyperarnmonemia exhibited similar symptoms, but in addition had severe 
ataxia. All animals with acute liver failure and acute hyperarnmonemia developed 
encephalopathy stage B, after 14.8±0.2 and 15.5±1.9 hours respectively (mean±SEM, 
n=6). Two rabbits with acute liver failure died just before decapitation. Control studies 
74 
Table I 
Mean arterial ammonia levels during acute ischemic liver failure and acute 
hyperammonemia. 
Model 
ALF 
AMM 
c 
44±7 j.<IDOl/1 176±16 
9±3 299±81 
33±10 28±14 
t, 
277±35 
430±85 
25±9 
400±43 
693±184 
41±16 
533±62 
955±120' 
34±18 
Values are derived from six experiments and are expressed as mean±SEM. 
ALF acute liver failure, AMM acute hyperammonemia, C controls, 
to start of the experiment, t.,·t,-t12 after 4,8 and 12 hours, t,. encephalopathy stage B. 
'p<0.05 AMM vs. ALF 
were performed for 14.7±1.8 hours (mean±SEM, n=6); among the control rabbits no 
spontaneous deaths occurred. 
Plasma ammonia levels 
During the experiments increases of arterial ammonia levels in the rabbits with 
acute liver failure and acute hyperammonemia showed a similar pattern. At the start of 
the experiments ammonia levels tended to be higher in rabbits with acute liver failure 
( 44 ± 7 !<mol/!), due to their portacaval shunt, when compared to rabbits with acute 
hyperammonemia (9±3 J.<IDOl/1) or controls (33±10 !<mol/l)(all three groups: 
mean±SEM, n=6). However, the difference did not reach statistical significance 
(p>0.05). During the experiments mean arterial ammonia levels tended to be higher 
among the rabbits receiving an ammonia infusion, but differences were not statistically 
different (table I). During encephalopathy stage B the difference in plasma ammonia 
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Table II 
One-point binding assay of [3H]MK-801 to synaptical membranes from normal rabbits and 
rabbits with severe encephalopathy stage B from acnte liver failure or acnte 
hyperammonemia. 
Brain area Model PHJMK-801 binding (pmol/mg protein) 
Hippocampus ALF 0.829±0.044 
AMM 0.809±0.031 
c 0.811 ±0.032 
Cerebral conex ALF 0.679±0.032 
AMM 0.656±0.038 
c 0.622±0.033 
Striatum ALF 0.453 ±0.020 
AMM 0.478±0.018 
c 0.480±0.029 
Data are derived from six experiments and are expressed as mean±SEM. 
ALF acute liver failure, AMM acute hyperammonemia, C controls. 
levels between rabbits with acute liver failure (533 ±62 l'molll) and rabbits with acnte 
hyperammonemia (955±120 !'ffiOI/1) reached statistical significance (p<0.05, 
mean±SEM, n=6)(table 1). 
fH]MK-801 binding to tbe MK-801 binding site of tbe NMDA receptor 
Homogenates were prepared from the hippocampus, cerebral conex and striatum 
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Table ill 
Saturation srudies on binding of rHJMK-801 to synaptical membranes from cerebral 
cortex of normal rabbits and rabbits with severe encephalopathy stage B from acute liver 
failure or acute hyperammonemia. 
Model 
ALF 
AMM 
c 
K,.1 (nM) 
1.62±0.36 
1.19±0.23 
2.09±0.38 
B_1 (pmollmg) 
0.63±0.07 
0.45±0.08 
0.79±0.14 
K,.2 (nM) 
265.8±195.9 
182.7 ± 152.7 
304.6±181.3 
B_2 (pmol/mg) 
7.29±4.92 
4.57±2.76 
4.65±1.99 
Data are derived from six experiments and are expressed as mean±SEM. 
ALF acute liver failure, AMM acute hyperammonemia, C controls. 
B_ expressed per mg protein. 
as these are major anatomic regions in which glutamate is used for neurotrausmission. In 
control rabbits rHJMK-801 binding to synaptical membranes in the one-point assay was 
high in the hippocampus, intermediate in the cortex and low in the striatum. No 
significant differences in rHJMK-801 binding were found in rabbits exhibiting severe 
encephalopathy stage B from acute liver failure or acute hyperammonemia (Table II). The 
single concentration of rHJMK-801 (3 nM) labels primarily the high affmity binding site 
(about80%) compared to the low-affmity binding site (about 20%)(see below). 
Saturation srudies of the binding of fH]MK-801 to homogenates from cerebral cortex 
demonstrated two different binding sites, one with low and one with high affmity. 
Compared to corresponding data for controls, the values for Kn and B_ were not 
changed in rabbits with encephalopathy from acute liver failure or acute hyperammonemia 
(table ill). 
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DISCUSSION 
The results of the present study indicate there are no significant alterations in the 
NMDA receptor population in cerebral cortex -and probably also in hippocampus and 
striatum- of rabbits with severe encephalopathy from acute liver failure or acute 
hyperammonemia. 
In this study heterogeneity of f'H]MK-801 bindiog sites was found, as reponed 
recently by other groups (31,32). As discussed before (25), the high affinity bindiog sites 
as found with the present technique may be identical to those found previously in rat 
brain (23). The exact nature of the low-affutity bindiog site is not clear at present. 
However, it has been proposed that ['H]MK-80!labels an additional binding site, for 
instance the nicotinic receptor channel (33-36). With increasing ligand concentrations in 
saturation experiments, the amount of specific binding is decreasing from about 75% to 
40% (24,25). With such low specific binding it is not possible to determine the I<. and 
B= values of the low-affinity bindiog site (I<, and B.,) with high precision. This may 
explain the scatter of the K, and B_, values. 
Results of previous smdies reponed on glutamate receptors in experimental hepatic 
encephalopathy have been conflicting (table IV)(37). In rabbits with galactosantine 
induced acute liver failure, f'H]glutamate binding was dintinished (38), which was 
subsequently shown to be the result of a decreased number of kainate receptors (39). 
However, in acute liver failure from hepatectomy aud tetrachloride in the rat ( 40), 
thioacetamide in the rat (41) and ischemic liver necrosis in the rabbit (present study) no 
changes were found, although in the latter we cannot exclude changes of the kainate and 
AMP A (arnino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptors. In rats with 
chronic hepatic encephalopathy, glutamate binding to the NMDA receptor was dintinished 
(42); in dogs with chronic hepatic encephalopathy, NMDA receptor bindiog appeared 
normal whereas changes occurred in the kainate and AMPA receptors (43). No changes in 
glutamate receptors were found in models of acute hyperammonemia in rabbits (38, 
present study). However, the number of all three subgroups of glutamate receptors were 
found to be diotinished in hypera.'lllllonemic rats (44). Thus, during experimental hepatic 
encephalopathy from acute liver failure there may be a selective loss of kainate receptors 
(38), with a preservation of NMDA receptors (present study). Chronic hepatic 
encephalopathy appears to be associated with variable changes of the glutamate receptor 
populations (42,43). Conflicting results have also been found during hyperammonemia 
(38,44 and present study). 
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Table IV 
Glutamate receptors in experimental hepatic encephalopathy. A review of the literature. 
First author (ref.) Animal Model Glutamate total NMDA 
Perenci (39) Rabbit Galactosamine K0 nc Brm.~ ' 
Perenci (38) Rabbit Hyperamrnonemia K0 nc Bmv; nc 
Watanabe (40) Rat Hepatectomy/CCI4 K0 nc Bmu nc 
Zinunem1an (41) Rat Thioacetarnide K0 nc Bmax nc 
Peterson (42) Rat Portacaval shunt binding I 
Maddison (43) Dog Congenital pc shunt K0 nc Bma:.; nc 
Rao (44) Rat Acute hyperammonemia K0 nc Bmu ' binding I 
Chronic .. K0 nc Bmu t 
Present study Rabbit Acute liver failure K0 nc Bmax nc 
Rabbit Acute hyperanunonemia K0 nc Bnw: nc 
' decrease, nc no change 
Kainate AMPA 
K0 nc Bmu ' 
binding nc binding nc 
K0 nc Bmu ' abolition of low 
affinity receptor 
binding nc binding nc 
Experimental acute hepatic encephalopathy and acute hyperannnonemia appear to be 
associated with increased extracellular glutamate levels (13,45,46). Increased glutamate 
concentrations in the cerebrospinal fluid of patients with hepatic encephalopathy suggest 
that increased extracellular brain glutamate also occurs clinically (14-16). Increased 
extracellular glutamate together with a normal NMDA receptor population, might lead to 
glutamate overexposure. In brain ischemia and epilepsy there is evidence indicating that 
prolonged glutamate exposure is deleterious to the brain (47). In these conditions most 
toxic effects of glutamate are thought to result from a prolonged depolarizing action at the 
postsynaptic receptor sites (48-49), in particular the NMDA receptor sites (18). This 
action is assumed to give rise to membrane permeability changes which lead to impaired 
ion homeostasis (48,49). Especially increased neuronal calcium influx may be responsible 
for ceil swelling and degeneration (50). Maybe this mechanism is also of importance in 
encephalopathy from acute liver failure and acute hyperannnonemia. 
In conclusion, the NMDA receptor population is normal during encephalopathy from 
acute liver failure and acute hyperannnonemia in the rabbit. In addition, as there is 
experimental evidence of increased extracellular brain glutamate concentrations in these 
conditions, the concept of glutamate overexposure should receive further anention in 
studies on the pathogenesis of hepatic encephalopathy. 
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SUMMARY 
In experimental hepatic encephalopathy and hyperammonemia extracellular levels 
of glutamate are increased in hippocampus and cerebral cortex. It has been suggested that 
oversthnulation of glutamate receptors causes a pathological calcium entry into neurons 
via receptor-operated (NMDA- and AMP A-type) or voltage-dependent calcium channels 
leading to calcium overload and cell death. Neurodegeneration as a result of exposure to 
excitotoxins, including glutamate, can be localized and quantified using 45CaCI2 
autoradiography. Ibis approach was used to study cerebral calcium accumulation in 
rabbits with acute liver failure and acute hyperammonemia. 
Acute liver failure was induced in 6 rabbits, acute hyperammonemia in 4 rabbits; 
4 control rabbits received sodium-potassium-acetate. At the start of the experiment 500 
I'Ci 45CaCI2 was given intravenously. Decapitation followed after development of severe 
encephalopathy. Autoradiographs were made from brain slices. The ratio dorsal 
hippocampus:backgrouod labelling in whole brain slices was calculated in 12 consecutive 
brain slices, to obtain the relative optical density in the dorsal hippocampus. 
All rabbits with acute liver failure and acute hyperammonemia developed severe 
encephalopathy, after 13.2±1.7 and 19.3±0.5 hours respectively (mean±SEM). Plasma 
ammonia levels were 425±46 and 883±211'mol/l, then, respectively (p<0.05). Control 
rabbits maintained nortnal plasma ammonia levels (13±5 l'mol/1), demonstrated normal 
behaviour throughout the study and were sacrificed after 16 hours. 
There was no increased 45Ca accumulation in the hippocampus of rabbits with 
severe encephalopathy from acute liver failure or acute hyperammonentia. This suggests 
that, despite increased extracellular brain glutamate levels in these conditions, glutamate 
neurotoxicity was not important for the development of encephalopathy in our rabbits. 
88 
INTRODUCTION 
Hepatic encephalopathy is a neuropsychiatric syndrome caused by serious liver 
disease. Hyperammonentia appears to be an important causative factor (1). Ammonia may 
disturb nonmal brain function in many ways (1,2), but the precise mechanism of ammonia 
toxicity in liver disease is unknown. 
The amino acid glutamate is the most common excitatory neurotransmitter in the 
manunalian brain (3) and the metabolism of glutamate is closely related to that of 
anunonia (4,5). Experimental acute hepatic encephalopathy and acute hyperammonemia 
appear to be associated with increased extracellular brain concentrations of glutamate 
(6-9). In addition, increased glutamate concentrations are also found in cerebrospinal fluid 
of patients with hepatic encephalopathy (10-12). Increased extracellular glutamate levels 
may cause overstimulati.on of glutamate receptors (ionotropic excitatory amino acid 
receptors: presynaptic kainic acid (KA), and postsynaptic a-antino-3-hydroxy-5-methyl-4-
isoxazole propionate (AMPA) and N-methyi-D-aspartate (NMDA)). In brain ischemia and 
epilepsy there is evidence indicating that prolonged glutamate exposure is deleterious to 
the brain (13,14). In these conditions most toxic effects are thought to result from a 
prolonged depolarizing action at the postsynaptic receptor sites (15,16), in particular the 
AMPA receptor sites (17). This action is assumed to give rise to membrane permeability 
changes which lead to impaired ion homeostasis (15,16). Especially increased neuronal 
calcium influx via opening of the NMDA receptor channel may be responsible for cell 
swelling and degeneration (18). Maybe this mechanism is also of importance in 
encephalopathy from acute liver failure and acute hyperanunonemia. 
The regional distribution of ischemic (19) or excitotoxic (20) brain damage can be 
visualized and quantified (21) using 45CaC12 autoradiography of brain sections. To 
determine whether excitotoxic brain injury is of importance in hepatic encephalopathy and 
anunonia toxicity, we performed 45CaCI2 autoradiography studies on brains from rabbits 
with encephalopathy from acute ischemic liver failure and acute hyperammonem.ia 
simulating acute liver failure. 
METHODS 
Animals 
12 New Zealand white rabbits weighing 2-3 kg were used; 6 rabbits with acute 
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liver failure, 4 rabbits with acute hyperammonemia and 4 control rabbits. 
Animal models 
Acute liver failure was induced by a two-stage liver devascularisation procedure as 
described earlier (22,23). Under anesthesia a laparotomy was performed: a loose ligature 
was placed around the hepatoduodenal ligament and guided thtough a plastic tube thtough 
the abdominal wall to the subcutaneous layer of the left subcostal region, and a small-
diameter (5 mm) side-to-side portacaval shunt was constructed. During this procedure the 
superior mesenteric artery was clamped to reduce splanchnic blood stasis. To correct 
acidosis after release of the vascular clamps, 5 ml 8.4% sodium bicarbonate were given 
intravenously. Postoperatively the rabbits were given 50 ml 10% glucose subcutaneously, 
followed by standard laboratory chow and water ad libitum. The second day after the 
operation acute ischemic liver failure was induced by tightening the loose ligature around 
the hepatoduodenal ligament after giving 50 mg amoxicillin intravenously. The rabbits 
were subsequently placed in a restraining box. To prevent hypoglycemia 10% glucose 
was given intravenously, starting at a volume of 3 mllhr and which was adjusted 
according to the plasma glucose level when necessary. 
Acute hyperammonemia was induced by a prolonged intravenous ammonium 
acetate (NH4Ac) iofusion as described earlier (23). After insertion of a Venflon cannula 
(diameter 0.8 mm, Viggo, Helsingborg, Sweden) into an earvein, NR,Ac was infused at a 
constant volume of 6 mllhr, starting with an initial dose of 0.8 mmol/kglhr, which was 
subsequently increased by 0.2 mmollkg/hr every two hours. After 16 hours the dose 
remained constant. 
Control rabbits received a sodium/potassium acetate (NaKAc) solution, which was 
infused -as far as the acetate concentration was concerned- as in the NR,Ac experiments. 
Clinical signs of encephalopathy 
During study all rabbits were kept in a restraining box. However, at regular time-
intervals the rabbits were put into a large cage for clinical evaluation. Clinical signs 
studied were spontaneous activity, body posture, righting reflex, presence of ataxia and 
reaction to a painful stimulus. In most rabbits with acute hepatic encephalopathy due to 
ischemic liver cell necrosis two stages of hepatic encephalopathy are easily recognizable 
(24). Stage A is characterized by a disturbed righting reflex: the animal will not get up 
hnmediately when placed on its side. At stage B, the rabbit lays in the cage and cannot 
achieve the sitting position, even after stimulation, and usually cannot lift its head. All 
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rabbits with ischemic liver cell necrosis and all rabbits receiving NH.,Ac were sacrificed 
by decapitation dnring encephalopathy stage B. The rabbits receiving NaKAc were 
sacrificed after 16 hours. 
Laboratory measurements 
Arterial blood samples were taken from all rabbits studied, just before the start of 
the experiment and dnring severe encephalopathy (stage B). Annuonia was determined 
with an enzymatic method (25). Blood glucose levels were measured hourly 
(Haemoglucotest, Boehringer, Germany). 
45CaClz autoradiography 
Autoradiography was essentially performed as described previously (20). Just 
before the induction of acute liver failure or the start of ammonium acetate or 
sodium/potassium acetate infusion radioactive calcium chloride (500 I'Ci 45CaCI2 
(Amersham) in 1 ml of saline) was given intravenously into an ear vene. With 
development of encephalopathy stage B, rabbits with acute liver failure or acute 
hyperammonemia were sacrificed by decapitation; control rabbits were sacrificed after 16 
hours. The brains were rapidly removed from the skull, immediately frozen in isobutanol, 
which was chilled with dry ice, and stored at -7fJ'C prior to further use. Coronal sections 
(30 !Lffi) through basal ganglia and hippocampus were cut in a cryostat at -2fJ'C, and 
thaw-mounted onto gelatin-chromalum coated glass slides, dried on a hot plate (40'C) and 
stored at room temperature in the presence of silica gel for 1 day. Subsequently, the dried 
sections were exposed to Jl-sensitive film (Hyperfllm Bmax, Amersham) in Kodak-X-0-
matic cassettes for 7 days and the film was developed in D19 (Kodak). 
Autoradiographs were analyzed in a semi-quantitative manner using relative optical 
density (ROD) aod computerized image analysis (MCID software, Imaging Research Inc., 
Brock University, St. Catherines, Canada). Autoradiographs of 45Ca standards indicated 
that, relative optical density and radioactivity increase linearly, up to 6 times background 
level (=ROD in control brain tissue), aod that a relative ROD increase of o% (versus 
background) represents a relative radioactivity increase (=45Ca increase) of 2o%. The 
ratio of ROD dorsal hippocampus versus ROD background (in the rest of the same brain 
section) was calculated for both hemispheres in 12 consecutive sections (distance between 
sections 60-90 I'm), to obtain the relative increase in ROD in the dorsal hippocampus of 
each animal. Using this approach a ratio of < 1 denotes decreased labelling, > 1 
increased labelling aod 1 unchanged labelling as compared to the rest of the brain. 
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After exposure to autoradiographic film brain sections were stained with thionine 
according to standard procedures. 
Necropsy 
After sacrifice of the auimals necropsy was performed to exclude gross 
pathological abnormalities. In the animals with acute ischemic liver cell necrosis the liver 
was examined carefully to comrrm tigbtening of the ligature. 
Statistics 
The results are presented as mean ± S.E.M. For statistical analysis unpaired 
Student's t test was used. Statistical significance denotes p<0.05. 
All experiments were approved by the Ethical Committee on Animal Research of 
the Erasmus University Rotterdam. 
RESULTS 
Clinical signs of encephalopathy 
Encephalopathy from acute liver failure was characterized by complete loss of 
spontaneous activity, impaired body posture, absence of the rigbting reflex and decreased 
muscle tone. One rabbit with acute liver failure developed ataxia. Rabbits with 
encephalopathy from acute hyperammonemia exhibited similar symptoms. but in addition 
all four rabbits developed ataxia. One rabbit with hyperammonemia developed generalized 
seizures and died spontaneously immediately thereafter. All auimals with acute liver 
failure and acute hyperammonemia developed encephalopathy stage B, after 13.2±1.7 
(n=6) and 19.3±0.5 (n=4) hours respectively (p>0.05). Control studies were performed 
for 16 hours; all four control rabbits exhibited normal behaviour at the end of the 
experiments. 
Plasma ammonia and glucose levels 
At the start of the experiments ammonia levels tended to be higber in rabbits with 
acute liver failure (86±22 !<IDOI/I), due to their portacaval shunt, when compared to 
rabbits with acute hyperammonemia (19±13 l'mol/1) or controls (25±9 !'moll!). 
However, the difference did not reach statistical significance (p>0.05). During 
encephalopathy stage B the difference in plasma ammonia levels between rabbits with 
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acute liver failure (425 ±46 l'mol/1) and rabbits with acute hyperammonemia (883 ±21) 
reached statistical significance (p<0.05). At the end of the control experiments ammonia 
levels had not changed (13±5 J<ffiOl!l). 
Hypoglycemia was not observed. In control rabbits plasma glucose levels were 
8.4±0.5 mmol/1 at the start, and 7.6±0.1 mmoVI (p>0.05) at the end of the 
experiments. In rabbits with acute liver failure these levels were 7.9±0.1 mmoVI and 
8.2±0.6 respectively (p>0.05); and in rabbits with acute hyperammonemia 9.0±0.4 
mmoVl and 16.4±2.8 mmol/1 respectively (p<0.05). 
45Ca-autoradiograpby 
Autoradiographs from control rabbits showed a diffuse greyish labelling of the 
brain slices, and no regional distribution of the label. Autoradiographs from rabbits with 
acute liver failure and acute hyperammonemia also showed a diffuse greyish labelling. In 
two rabbits with acute liver failure and in one rabbit with acute hyperammonemia a slight 
increased labelling of the hippocampal region could be seen (figure Ia). However, 
quantification of the ratio of ROD hippocampus versus ROD background (=ROD 
surrounding brain tissue in the same section), revealed no significant differences between 
rabbits with acute liver failure, acute hyperanunonemia and controls (table 1). In addition, 
the histology of the hippocampal pyramidal cell layer in the sections used for 
autoradiography, appeared to be normal in both rabbits with acute liver failure and acute 
hyperammonemia (data not shown). Finally, also in striatum, or any other brain area in 
the forebrain of rabbits with acute liver failure or acute hyperammonemia, no 45Ca 
accumulation was found (figure 1b). 
DISCUSSION 
The present results show that there is no 45Ca accumulation in the brains of rabbits 
with severe encephalopathy from acute liver failure or acute hyperammonemia. Thus, 
despite fmdings of increased extracellular brain levels of glutamate ( 6-9), as well as 
increased brain tissue and cerebrospinal fluid levels of the excitotoxin quinolinic acid in 
both clinical and experimental hepatic encephalopathy (26,27), we could not demonstrate 
excitotoxic brain damage in experimental acute hepatic encephalopathy using 45CaC12 
autoradiography. The latter technique has been shown to be a sensitive tool to 
demonstrate cerebral calcium accumulation. in pathological conditions associated with 
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Figure la and lb 
45Calcium-autoradiographs of coronal brain slices, from a rabbit with acute liver failure. 
through the hippocampus (a) and basal ganglia (b). Maguificatiou 3x. 
cx=cortex, hp=hippocampus, bg=basal ganglia. vt=ventricle. 
excitotoxicity (19-21,28). Furthermore, increases of extracellular brain glutamate, during 
cerebral ischemia (3.5-8 fold)(29) and hypoglycemia (2.5 fold)(30), conditions considered 
to be associated with glutamate related neurototoxicity, are similar to those found during 
acute liver failure (6-8). However, glutamate levels obtained in brain dialysates are a 
resultant of release from the transmitter pool, leakage of metabolic glutamate from 
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TABLE 
Ratio of relative optical density (ROD) of the hippocampal region and relative optical 
density of the background in brains from rabbits with acute liver failure and acute 
hyperammonemia. 
Experimental animal Hippocampus, left Hippocampus, right 
ALF I 1.011 ±0.014 1.002±0.014 
2 0.997 ±0.017 0.999±0.016 
3 1.024±0.011 1.017±0.009 
4 1.021 ±0.015 0.965±0.009 
5 0.943±0.010 0.907±0.014 
6 1.003±0.007 0.975±0.010 
mean±SEM 1.000±0.012 0.978±0.016 
AMM 1 0.961 ±0.014 0.909±0.007 
2 0.925±0.011 0.918±0.011 
3 0.979±0.012 0.97)±0.016 
4 0.978±0.011 0.950±0.010 
mean±SEM 0.961±0.013 0.937±0.014 
c 1 0.979±0.011 0.954±0.010 
2 0.937 ±0.006 0.930±0.010 
3 1.020±0.006 0.993±0.007 
4 1.021 ±0.011 1.009±0.015 
mean±SEM 0.989±0.020 0.972±0.018 
ALF acute liver failure, AMM acute hyperammonemia and C control rabbits. 
Ratios in individual rabbits represent the mean±SEM of 12 consecutive brain slices. 
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different cell types and of the uptake by high affinity glial and presynaptic glutamate 
uptake systems. Since several attempts to detect changes in extracellular glutamate during 
both normal and pathophysiological neuronal stimulation, which is supposed to release 
glutamate into the synaptic cleft, have failed (31), it is questionable whether glutamate in 
brain dialysates is a good indicator of the glutamate concentration in the excitatory 
synaps. Thus, increased extracellular brain concentrations of glutamate following 
experimental acute liver failure, may not be able to stimulate AMP A or NMDA receptors 
in order to precipitate excitotoxic injury. 
Another explanation for our negative results, may be the relative short duration of 
the pathological condition. After ischemic or excitotoxic brain injury, calcium 
accumulation and cell death increase up to at least three days after the initial insult (21). 
We have studied our animals 12-20 hours after the induction of acute liver failure or 
acute hyperammonemia, i.e. the duration of significant increased extracellular glutamate 
was even less (6). Thus, in our experimental models there might have been not enough 
time to develop excitotoxic brain damage. This possible explanation, of course, should be 
tested in more chronic models of encephalopathy. 
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SUMMARY 
Neuronal and glial cell marker proteins were quantified in order to evaluate the 
possibility of increased proteolysis in the brain of rabbits with acute liver failure and 
acute hyperammonemia. Acute liver failure was induced by a two-stage liver 
devascularization procedure. Acute hyperammonemia was induced by a prolonged 
infusion of ammonium acetate. whlch simulates the plasma ammonia level in acute liver 
failure. Control animals received an infusion of sodium/potassinm acetate. After 
development of severe encephalopathy, the animals were sacrificed (13.7±1.3 hours for 
rabbits with acute liver failure and 20.2±0.8 hours for rabbits with hyperanunonemia 
[n=6, mean±SEM]) and their brains were dissected into cerebral cortex, hippocampus, 
cerebellum and brain stem. The total protein content and the concentrations of the 
neuronal cell marker proteins NSE (neuron specific enolase), NF-68 and NF-200 (68 
kDA and 200 kDA neurofiiament polypeptides) and the glial cell marker proteins GF AP 
(glial fibrillary acidic protein) and S-100 were determined. Total protein content was 
decreased in the brain stem in acute hyperammonemia only. The content of neuronal and 
glial cell markers was not affected in either of the two conditions. However, low 
molecular weight proteolytic fragments of the NF-68 polypeptide were observed in the 
hippocampus of three out of six animals in both experimental groups. No proteolytic 
degradation of GF AP was observed. 
The results show that, in experimental encephalopathy due to acute liver failure 
and acute hyperammonemia, no major changes occur in the marker proteins. The fmding 
of proteolytic fragments of the NF-68 polypeptide indicates that the neuronal population is 
affected prior to glial alterations. These fmdings are in agreement with the concept that 
acute hepatic encephalopathy is reversible and induces only slight structural changes. 
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INTRODUCTION 
Hepatic encephalopathy is a neuropsychiatric syndrome caused by serious liver 
disease. Hyperammonemia appears to be an important causative factor (1). Ammonia 
disturbs normal brain function in many ways (1,2), but the precise mechanism of 
ammonia toxicity is unknown. We have concentrated on the interference of 
hyperanrmonemia with excitatory neurotransmission (3,4). 
The amino acid glutamate is the most common excitatory neurotransmitter (5) and 
the metabolism of glutamate is closely related to that of anrmonia (6,7). Increased 
extracellular concentrations of glutamate were found, in the brain of rabbits with acute 
ischemic liver necrosis, galactosamine~induced liver necrosis and acute hyperammonemia 
(3,4) and in the cerebral spinal fluid of rats with acnte liver failure (8). Furthermore, 
increased glutamate concentrations have been demonstrated in the cerebrospinal fluid of 
patients with hepatic encephalopathy (9-11). This indicates that the receptors are exposed 
to an increased glutamate level in conditions of hyperanrmonemia. In vitro experiments 
have shown that hyperanrmonemia compromises glutamate re-uptake by astrocytes 
(12,13). Moreover, astrocytes are critical for anrmonia metabolism (7,13) and the most 
characteristic neuropathological fmding in hepatic encephalopathy is the transformation of 
astrocytes in grey matter into Alzheimer type II glia (13-15). 
The extracellular brain glutamate concentration is found to increase 3.5-10 fold in 
brain ischemia (16) and this is considered crucial to the development of neuronal deficits 
and cell death in stroke, hypoglycemia and epilepsy (17). In brain ischemia, glutamate 
toxicity is mediated mainly through activation of postsynaptic receptors. The neurons 
swell within minutes (18) and die within a day due to excessive calcium influx (19,20). 
The extracellular brain glutamate concentration is increased 2-5 fold in experimental acute 
liver failure (3,4). Consequently, glutamate neurotoxicity may also be of importance in 
the pathogenesis of hepatic encephalopathy. 
Glutamate receptor mediated neurotoxicity induces degenerative and/ or 
proliferative changes in the brain. The concentrations of neuronal and glial cell marker 
proteins have been used to monitor these effects. These markers include: neuron specific 
enolase (NSE), a neuronal cytoplasmic enzyme (21,22), NF-68 and NF-200, two 
polypeptide fragments of neuronal intermediate fl.laments (23), glial fibrillary acidic 
protein (GFAP), a fibrillary component of the glial intermediate fl.lament (24) and S-100 
which is a glial cytoplasmic protein (21). The appearance of breakdown products of 
neuronal and glial intermediate filaments is a sensitive indicator of excitatory cell injury 
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(25). This report concerns degenerative and proliferative changes in neurons and glial 
cells in experimental acute liver failure and acute hyperammonemia. 
METHODS 
Animals 
18 New Zealand white rabbits weighing 2-3 kg were used. 
Animal models 
Acute liver failure (ALF) was induced by a two-stage liver devascularization 
procedure as described earlier (26,27). Under anesthesia a laparotomy was performed: a 
loose ligature was placed around the hepatoduodenal ligament and guided through a 
plastic tube through the abdominal wall to the subcutaneous layer of the left subcostal 
region, and a small-diameter (5 mm) side-to-side portacaval shunt was constructed. 
During this procedure the superior mesenteric artery was clamped to reduce splanchnic 
blood stasis. To correct acidosis after release of the vascular clamps, 5 ml 8.4% sodium 
bicarbonate were given intravenously. Postoperatively the rabbits received 50 ml 10% 
glucose subcutaneously. followed by standard laboratory chow and water ad libitum. The 
second day after the operation acute liver failure was induced by tightening the loose 
ligature around the hepatoduodenal ligament after giving 50 mg amoxicillin intravenously. 
The rabbits were subsequently placed in a restraining box. To prevent hypoglycemia 10% 
glucose was given intravenously, starting at a volume of 3 mllhr and adjusted accotding 
to the plasma glucose level when necessary. If survival after induction of liver ischemia 
was less than 6 hours, death was considered to be related to postoperative complications. 
Only rabbits surviving for at least 6 hours were included in the analysis. 
Acute hyperammonemia (AMM) was induced by a prolonged intravenous 
ammonium acetate (NR,Ac) infusion simnlating the plasma ammonia pattern of the rabbits 
with acute liver failure (27). After insertion of a Venflon cannula (diameter 0.8 mm, 
Viggo, Helsingborg, Sweden) into an ear vein, NH.,Ac was infused at a constant volume 
of 6 ml/hr, starting with an initial dose of 0.8 mmol/kglhr and increasing the dose by 0.2 
mmol/kg/hr every two hours for 16 hours. Control rabbits (C) received a 
sodium/potassium acetate (N aKAc) solution, which was infused as in the NH.,Ac 
experiments. 
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Laboratory measurements 
Anerial blood samples were taken at 0,1 and 2 honrs, and then every two hours 
thereafter for ammonia determination, using an enzymatic method (28), Blood glucose 
levels were measured hourly (Haemoglucotest, Boehringer, Germany). 
Clinical signs of encephalopathy 
At regular intervals the rabbits were put into a large cage for clinical evaluation. 
Rabbits with acute liver failure exhibit two easily recognizable stages of encephalopathy 
(29), Stage A is characterized by a disturbed righting reflex: the animal will not get up 
intmediately when placed on its side. In stage B the rabbit lies in the cage and cannot 
achieve the sitting position, even after stimulation, and cannot lift its head. All rabbits 
with acute liver failure and all rabbits receiving NR,Ac were sacrificed during 
encephalopathy stage B. The rabbits receiving NaK.Ac were sacrificed at the same time as 
the rabbits receiving NR,Ac. All animals were sacrificed by decapitation. 
Brain sampling 
Brains were rapidly removed and dissected. Dissection was performed on a plastic 
plate, placed on ice. Cerebral cortex (left and right fronto-temporal parts), hippocampus 
(left and right), cerebellum and brain stem were dissected. The samples were packed 
intmediately in plastic bags, which were stored at -70'C until further analysis. 
Quantitative analysis of neuronal and glial cell marker proteins 
Brain samples were sonified at 90"C and a dot intmunobinding procedure was 
performed (25,30): brain samples were diluted in buffer (120 mM KCl, 20 mM NaC!, 2 
mM NaHC03 and 5 mM Hepes, pH 7.4/0.7% Triton X-100 (vol/vol) to a concentration 
of ca. 0.5 Ji-g total protein per Ji-l. Using the Minifold IT slot-blot apparatus as a template, 
20 JJ-l samples were bloned onto nitrocellulose membrane filters. The filters were fixed in 
10% acetic acid and 25% 2-propanol. The remaining reactive sites on the filters were 
blocked with a blocking solution containing 0.5% gelatin. The filters were incubated 
overnight at room temperature in an antibody solution (blocking solution, 0.1% Triton 
X-100 and antisera). The antibody preparations were diluted as follows: S-100, 1/500; 
GFA, 1/2500; NSE, 1/500; NF-68, 1/500 and the supernatant of the monoclonal antibody 
FE3 against NF-200, 11100. The specificities of the antibodies have been described in 
detail (24). After antibody incubation, the filters were reacted with 1251 -protein A in the 
blocking solution containing 0.1% Triton X-100 at a radioactivity of 150,000-200,000 
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cpm/ml. Finally the frlters were dried, cut and assayed for radioactiviry in a gamma 
counter (Automatic Gamma Counter and Sample Change System 54, Nuclear Data Inc.). 
For determination of the NF-200 polypeptide with a monoclonal antibody, rabbit 
inrmunoglobulins to mouse inrmunog!obulins (diluted 1: I 000 in the antibody solution) 
were used as bridging antibodies since protein A binds very weakly to mouse 
inrmunog!obulins. The amount of each of the specific proteins in the unknown samples 
was quantified. First, a reference sample was prepared from a mixture of all control 
samples from the frontotemporal cerebral cortex and standard curves were constrncted by 
means of dilution. The amount of protein was found by interpolation of the standard 
curves. It was expressed in arbitrary units (AU), defmed as the amount of protein in 
20 J.<l of the reference sample. The total protein concentration in the samples was 
detennined with a commercial assay (Pierce) on nticrotiter plates. Bovine senun albmnin 
was used as a standard (30). 
Qualitative analysis of neuronal and glial intermediate fllaments 
Equal amounts of proteins applied to SDS-PAGE gels were separated by 
electrophoresis with a linear 6-12 % acrylantide gradient (31). The proteins were then 
transferred to 0.45 I'm nitrocellulose membranes (Schleicher & Schuell, Keen, NH, USA) 
for antibody incubation (32). The antibody preparations were diluted in the following 
manoer: rabbit anti-human GFA, 11!0000 and rabbit anti-bovine neurofrlament NF-68, 
1/1000. Preparation of the rabbit antisera used in this study, as well as determination of 
their specificities, was described elsewhere (33). Goat-anti-rabbit IgG-alkaline 
phosophatase was used as the secondary antibody and BCIP/NBT as substrate (BIO-RAD, 
Richmond, CA, USA). 
Necropsy 
Necropsy was performed to exclude gross pathological abnormalities. In the 
animals with acute ischemic liver necrosis the liver was examined carefully to confirm 
tightening of the ligature. 
Statistics 
The results are presented as mean±S.E.M .. For statistical analysis the unpaired 
Student's t test and the Student-Newman-Keuls procedure were used. Statistical 
significance was indicated by p<0.05. All experiments were approved by the Ethical 
Comntittee on Animal Research of the Erasmus Universiry Rotterdam. 
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Table I 
Mean arterial ammonia levels (in !'ffiOlfl) during acute liver failure, 
acute hyperammonernia and control experiments. 
c 
ALF 
AMM 
51±4 
120±24* 
49±3 
40±5 
247±26* 
216±23* 
t, 
33±1 29±2 35±3 
313±37* 481±109* 518±97* 
315±34* 370±39* 535±117* 
C controls, ALF acute liver failure, AMM acute hyperammonernia. 
to start of the experiment, t, after 4 hours etc., t,, end of experiment 
during severe encephalopathy (stage B). 
Values are expressed as mean±SEM; each group consisted of 6 rabbits. 
* p<0.05 with respect to controls (Student-Newman-Keuls test). 
RESULTS 
Clinical signs of encephalopathy 
Encephalopathy due to acute liver failure was characterized by complete loss of 
spontaneous activity, impaired body posture, absence of the righting reflex, decreased 
muscle tone and a diminished reaction to a painful stimulus. Rabbits with encephalopathy 
due to acute hyperammonernia exhibited similar symptoms but also had severe ataxia. All 
animals with acute liver failure and all animals with acute hyperammonernia developed 
encephalopathy stage B after 13.7±1.3 and 20.2±0.8 hours respectively (n=6, 
mean±S.E.M., p< 0.05). Two rabbits with acute liver failure died just after stage B was 
recognized. Control studies were performed for 18-20 hours. 
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Table ll 
Brain total protein content (!'g/mg wet weight) in acute liver failure, 
acute hyperammonemia and control experiments. 
c ALP AMM 
Cortex1 73±1.5 73±1.4 73±1.2 
Hippocampus' 83±1.1 86±1.3 81±1.4 
Cerebellum 72±0.4 74±2.3 70±1.3 
Brainstem 66±1.0 66±1.1* 60±1.9* 
C controls, ALP acute liver failure, AMM acute hyperammonemia. 
'Values are the mean of two (left and right) samples. 
Each group consisted of 6 rabbits. Values are expressed as mean±SEM. 
*p < 0.05 AMM with respect to C, and ALP with respect to AMM (Smdent-Newman-
Keuis test). 
Plasma ammonia levels 
During the experiments the increases in the arterial ammonia levels in rabbits with 
acute liver failure and acute hyperammonernia were similar in pattern. At the start of the 
experiments ammonia levels were significantly higher in ALP-rabbits (120 ±24 !'mol/!), 
due to their portacaval shunt, compared to AMM- (49±3 l'mol/1) or C-rabbits (51±4 
!<ffiOIII)(p<0.05). During encephalopathy stage B, the plasma ammonia levels in ALP-
rabbits (518±97 !'mol/!) and AMM-rabbits (535±117 !'mol/!) did not differ significantly 
(p>0.05)(table !). 
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Table ill 
Neuronal and glial marker proteins (AU/mg wet weight) in acute liver failure, 
acute hyperammonemia and control experiments. 
Cerebral cortex 1 c ALF AMM 
GFAP 0.91±0.11 0.80±0.04 0.93±0.16 
S-100 0.95±0.04 0.98±0.04 0.96±0.06 
NSE 0.79±0.03 0.84±0.03 0.78±0.04 
NF-68 0.84±0.04 0.83±0.03 0.94±0.06 
NF-200 0.86±0.06 0.85±0.07 0.85±0.08 
Hippocampus' c ALF AMM 
GFAP 0.93±0.10 0.82±0.04 0.95±0.11 
S-100 0.94±0.05 0.95±0.03 0.93±0.06 
NSE 0.84±0.04 0.86±0.05 0.78±0.02 
NF-68 0.83±0.02 0.88±0.06 0.81±0.05 
NF-200 0.70±0.05 0.69±0.03 0.69±0.06 
C controls, ALF acute liver failure, AMM acute hyperammonemia. 
1 Values are the mean of two (left and right) samples. Values are expressed in arbitrary 
units (AU), defmed as the amount of protein in 20 1'1 of a reference sample (see 
methods). Each group consisted of 6 rabbits. Values are expressed as mean±SEM. 
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Total protein content and neuronal and glial cell marker proteins 
Total protein content was measured in cerebtal cortex, hippocampus, brain stem 
and cerebellum (table II). Doring acute liver failure no changes in the total protein 
content were found. Doring acute hyperammonemia the total protein content of the brain 
stem was found to be decreased, compared to control rabbits (p<0.05); no changes were 
found in cortex, hippocaropus and cerebellum. The amounts of the neuronal (NSE, NF-68 
and NF-200) and glial (GFAP and S-100) cell marker proteins, in the cerebral cortex and 
hippocaropus, during acute liver failure and acute hyperammonemia were not different 
from those found in control rabbits (table III). Similar results were obtained in the 
cerebellum and brain stem (not shown). 
Qualitative alterations of glial and neuronal intermediate filaments 
Sonified brain samples containing equal amounts of the NF-68 polypeptide and the 
GFAP from the hippocampus, were investigated by the immunoblot technique using 
polyclonal rabbit antisera against the polypeptides (25). In both experimental groups, 
three out of six experimental animals, showed a visnal increase -compared to the controls-
in low molecular breakdown products of the neurofllament 68 kD polypeptide with 
molecular weights of 46 and 48 kD (figure 1). The increase seemed to be more 
pronounced among the animals infused with anunonia. No alterations of the immunoblot 
staining pattern, of GFAP from the hippocaropus of these animals were detectable (not 
shown). 
DISCUSSION 
The concentrations of neuronal (NSE. NF-68 and NF-200) and glial (GF AP and 
S 1 00) cell markers were unaffected in experimental encephalopathy, due to acute liver 
failure and acute hyperammonemia; the total protein content was lowered only in the 
brain stem of animals infused with ammonia. However, an increased amount of low 
molecular breakdown products of NF 68kD was found in the hippocampus of both treated 
groups. 
The degradation pattern of NF-68 is similar to that induced by calcium activated 
neutral proteases in vitro (34), since the major breakdown products have an approximate 
molecular weight of 50 kD. Similar breakdown products were observed after in vivo 
stimulation of hippocampal NMDA receptors in rats (25). 
110 
<~~~68 
1 2 3 4 5 6 7 8 9 
Figure 1 
Immunoblots of NF68-Iike polypeptides in the rabbit hippocampus after acute liver failure 
(lane 2,5,8) and after acute hyperammonemia (lane 3,6,9), as compared to controls (lane 
1,4,7). 30 l'g tissue protein were applied to each lane and rabbit anti-bovine NF-68 serum 
was used for detection. Molecular weights (kD) are indicated to the right of the 
innnunoblots. 
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Changes in glial proteins are the principal finding in hepatic encephalopathy. 
Cu!rured astrocytes showed a selective decrease in GF AP after four days of exposure to 
10 mM ammonium chloride (35), and there was a selective loss of GFAP in the grey mat-
ter of patients who died of liver cirrhosis and Alzheimer type IT gliosis (36,37). 
Alzheimer type IT astrocytes are not seen until after 5-10 days of treatment (15,38,39). 
The mechanism for this loss of GF AP is unknown. Increased calcium-dependent 
proteinase activity and decreased protein synthesis have been proposed (35,40). This 
specific loss of GFAP is a "marker" for hepatic encephalopathy; other pathological 
conditions invariably show an increase of GF AP (13). Predominantly structural proteins 
appear to be affected in hepatic encephalopathy, since the content of S-100 is not altered 
(41,42). 
The exposure time (less than 24 hours) in the present study may have been too 
short for quantitative changes in the proteins to occur. The qualitative change in NF-68 
seen in the hippocampus of animals with acute liver failure and acute hyperammonemia, 
indicates the involvement of calcium-activated proteolytic enzymes. This could be the 
result of (early) NMDA-receptor mediated neurotoxicity (18); however, quantitative 
neurofll.ament degeneration is Jacking. Whether these fmdings are of importance for the 
pathogenesis of hepatic encephalopathy remains uncertain. More experimental work on 
this issue is needed in animal models simulating chronic hepatic encephalopathy. 
However, the results are in agreement with the concept that acute encephalopathy 
due to acute liver failure or acute hyperammonem.ia is a reversible condition (43), which 
is not characterized by extensive structural changes in the brain. 
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CHAPTER 7 
Discussion. 
What is the mechanism of ammonia toxicity in hepatic encephalopathy? 
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INTRODUCTION 
Ammonia appears to fullfilllargely the requirements named by Zieve (1), for a 
substrate to be considered a toxin relevant for the development of hepatic encephalopathy: 
L patients presenting with hepatic encephalopathy usually have elevated plasma ammonia 
levels (2), 2. the administration of ammonia to patients with liver disease or to animals 
induces encephalopathy (3,4), and 3. the treatment modalities aimed at lowering plasma 
ammonia levels are the most effective (5). The exact mechanism how hyperannnonentia 
contributes to the development of encephalopathy in liver disease is, however, still 
unlmown. Here we will attempt to summarize the pathophysiology of hyperarnmonentia, 
and to assess its significance in the pathogenesis of hepatic encephalopathy. 
In theory, toxins may irdluence central nervous system functioning at three levels: 
L basic cell metabolism (e.g. pH regulation, water and energy balance), 2. 
electrophysiologic membrane function (e.g. ionic pumps) and 3. biochentical 
communication between neurons (i.e. synaptic neurotransmission). Ammonia has been 
shown to interfere with brain function at all three levels. 
BASIC CELL METABOLISM 
In hepatic encephalopathy there is a decrease of brain cell metabolism, reflected 
by decreased oxygen and glucose consumption (6). Recently it was shown that the 
changes in cerebral blood flow and glucose consumption, in patients with liver cirrhosis 
are comparable to those in experimental hyperannnonentia in animals (7,8). These 
fmdings are highly suggestive for ammonia being the cause of decreased brain 
metabolism. Whether decreased brain metabolism is a direct effect of ammonia or is a 
reflection of lower energy demand because of lower neuronal activity, is not yet known. 
Brain edema, an important complication of acute liver failure (9), reflects 
disturbed cerebral water balance. Brain edema also occurs in experimental acute liver 
failure and hyperammonentia (4,10-12). Probable mechanisms are inhibition of neuroual 
Na+ -K• -ATPase and disturbances of the integrity of the blood-brain barrier (13,14). 
Recently, the accumulation of osmogenic amino acids such as glutamine, which increases 
during hyperannnonentia, has been proposed to contribute to the development of cerebral 
edema in acute liver failure (15). These fmdings demonstrate the relevance of older 
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studies in which methionine sulfoximine, an inhibitor of glutamine synthesis, was showo 
to delay ammonia induced neurological deterioration in mice (16). The beneficial effects 
of methionine sulfoxintine were confirmed recently (17). Others have proposed that cell 
swelling could be the result of activation of a calcium-dependent pathway (12). In this 
regard our fmdings of increased extracellular brain glutamate levels during experimental 
acute liver failure and acute hyperammonemia in relation to excitotoxicity are of 
particular interest (see below)(18). 
ELECTROPHYSIOLOGJC MEMBRANE FUNCTION 
Ammonia disturbs the generation of both inhibitory and excitatory postsynaptic 
potentials. Under normal conditions the inhibitory neurotransmitters GABA and glycine 
open chloride channels after binding to their receptors. This induces hyperpolarisation 
through an influx of chloride, and the neuron looses its ability to fire (19). Ammonia 
inactivates the chloride extrusion from neurons (20), thereby abolishing the concentration 
gradient for chloride across the neuronal membrane. As a consequence, the opening of 
chloride channels by GABA or glycine is no longer followed by an influx of chloride into 
the neurons. Thus ammonia impairs postsynaptic inhibition in cerebral cortex, thalamus, 
brainstem and spinal cord (21). 
Ammonia decreases intracellular potassium and increases extracellular potassium, 
by a mechanism yet unknowo (22-24). However, this has a depolarizing effect on 
neurons, which interferes with the generation of excitatory postsynaptic potentials (21). 
The changes in intra- and extracellular potassium may result in a presynaptic conduction 
block (25), which means that a decreased number of synaptic terminals excrete the 
excitatory neurotransmitter glutamate on postsynaptic neurons. Consequently, the 
excitatory synaptic potential decreases, and thereby the generation of action potentials in 
the postsynaptic neurons. This can reduce excitatory neurotransmission (21). 
BIOCHEMICAL COMMUNICATION BETWEEN NEURONS 
The effects of annnonia on synaptic biochemical neurotransmission are mainly 
mediated through glutamate. A large portion of central mammalian neurons use the amino 
acid glutamate as an excitatory neurotransmitter (26), and the metabolism of glutamate is 
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related closely to that of ammonia (27). In vitro and in vivo experiments, have shown that 
ammonia alters brain glutamate homeostasis. Whole brain glutamate contents were found 
to be diminished during hepatic encephalopathy or hyperammonemia in patients as well as 
animals (28-31). Thus, it was assumed that encephalopathy could originate from an 
ammonia induced deficit of glutamate. However, these were whole brain studies in which 
the total amount in all anatomical compartments (vascular, intracellular and extracellular) 
was assessed. The concentration of a neurotransmitter in the synaptic cleft, a part of the 
extracellular space, is probably the best reflection of neurotransmitter ftmction. Since less 
than I% of the total amount of amino acid in the brain is found in the extracellular space, 
total brain measurements are not suitable for determining neurotransmitter ftmction (32). 
Extracellular brain glutamate concentrations appear to be increased (19,33-35). Increased 
glutamate concentrations in cerebrospinal fluid of patients with hepatic encephalopathy 
suggest that increased glutamate levels also occur clinically (36-38). 
Increased extracellular glutamate levels in the brain may have two effects: it could 
lead to compensatory down-regulation of glutamate receptors and/or there could be a 
direct toxic effect. Results in experimental animals are conflicting with regard to receptor 
changes, some have found evidence for down-regulation (39-43), whereas others did not 
fmd any changes (44-46). Differences in outcome may have been caused by differences in 
animal models used, with more changes occurring in more chronic models. The only 
study on patients with chronic liver disease published until now, also failed to 
demonstrate changes in the glutamate receptor (NMDA-subtype)(47). Most investigators 
have studied only one subtype of glutamate receptors or have measured total glutamate 
binding. With the increasing knowledge on different subtypes with different ftmctions it is 
important that a clear distinction between all the known glutamate receptor subtypes is 
made (NMDA, kainate and AMPA)(48). 
Toxic effects may result from increased extracellular concentrations. It is logical to 
assume that, especially with a normal number of glutamate receptors, increased 
extracellular glutamate levels may lead to glutamate overexposure. In brain ischemia and 
epilepsy there is evidence indicating that prolonged glutamate exposure is deleterious to 
the brain ( 49). In these conditions most toxic effects of glutamate are thought to result 
from a prolonged depolarizing action at the postsynaptic receptor sites (50,51), in 
particular the NMDA receptor sites (48). This action is assumed to give rise to 
permeability changes, which lead to impaired ion homeostasis (50,51). Especially 
increased calcium influx may be responsible for cell swelling and degeneration (52). Until 
now only a few studies on glutamate toxicity and/ or calcium metabolism in hepatic 
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encephalopathy and hyperammonemia have been reported. Ammonia decreases the 
calcium concentration in primary astrocyte cultures (53). No cbanges were found in 
brains from rabbits with acute liver failure or acute hyperammonemia using 45Ca-
autoradiography (54). The fmding of proteolytic peptide fragments in the brains of rabbits 
with acute liver failure and acute hyperammonemia, suggests that hepatic encephalopathy 
and hyperammonemia may be associated with some excitotoxic brain damage (55). 
However, based on these studies important excitotoxic brain damage in hepatic 
encephalopathy appears rather unlikely, although this topic warrants further study. 
In summary, ammonia has a variety of biochemical and neurological effects. Most 
important seem the effects on electrophysiologic membrane function (disturbance of the 
generation of inhibitory and excitatory postsynaptic potentials) and on glutamate 
neurotransmission and metabolism. The accumulation of glut:arnine may be basic to the 
development of brain edema. Based on current knowledge about ammonia toxicity, it is a 
challenge for future studies not to investigate whether ammonia has a role in the 
development of hepatic encephalopathy, but to improve our understanding of the major 
toxic actions of ammonia and to make them amenable to manipulation, i.e. treatment. 
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CHAPTER 8 
Summary and conclusions!Samenvatting en conclusies 
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SUMMARY AND CONCLUSIONS 
Ammonia has been considered the prime toxin in the pathogenesis of hepatic 
encephalopathy. However, because the correlation between plasma ammonia and degree 
of encephalopathy is often found to be poor, the ammonia hypothesis has been rejected by 
many. Currently, there is renewed interest for ammonia and its role in the development of 
hepatic encephalopathy. 
For a substrate to be considered a toxin, relevant for the development of hepatic 
encephalopathy, three criteria should be fu!lfilled: 1. the toxin should be present in 
abnormally high amounts in the presence of hepatic encephalopathy, 2. adntinistration of 
the substrate should induce hepatic encephalopathy, and 3. correction of the abnormality 
should reverse hepatic encephalopathy. Indeed, ammonia fullfllls these criteria largely 
(chapter 1). The aim of this thesis was to study the mechanism of ammonia toxicity in 
hepatic encephalopathy. 
Hepatic encephalopathy has been thought of as a dysbalance between inhibitory 
and excitatory neurotranstnitters. Glutaminase, an enzyme essential for the formation of 
glutamate, is inhibited by ammonia. Thus it was assumed that ammonia decreases the 
amount of glutamate in the brain, which would probably have an effect on normal brain 
function. Subsequently, the amount of glutamate was shown to be decreased in autopsied 
brain tissue. However, these were whole brain studies in which the total amount of 
glutamate was assessed in all anatomical compartments together. The concentration of a 
neurotransmitter in the synaptic cleft, a part of the extracellular space, is probably the 
best reflection of neurotranstnitter function. Since less than 1% of the total amount of 
antino acid in the brain is found in the extracellular space, total brain measurements are 
not suitable for determining neurotranstnitter function. The brain dialysis technique has 
made the extracellular space more accessible for research. Therefore, we decided to use 
brain dialysis in the study of brain glutamate in experimental hepatic encephalopathy. 
Reproducible animal models are needed for the study of hepatic encephalopathy. 
In the rabbit we induce acute ischemic liver necrosis and acute hyperammonemia. In the 
latter model plasma ammonia levels found in acute ischemic liver necrosis are simulated. 
Our animal models appear reproducible and suitable to be used in the study on hepatic 
encephalopathy and ammonia toxicity (chapter 2): encephalopathy develops in all animals 
studied, and drop outs occur seldomly. There are important resemblances: in both 
models, encephalopathy is characterized by loss of spontaneous activity, loss of body 
posture, disappearance of the righting reflex and hypotonia; ataxia is observed more 
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frequently in acute hyperammonemia. Extrahepatic complications, which occur in both 
models are cerebral edema and lactic acidosis; renal failure, hypothermia and sepsis only 
occur in acute ischemic liver necrosis. 
Using the brain dialysis technique in the cortex of rabbits with acute liver failure 
and acute hyperarmnonemia, we could not find a decrease of neurotransmitter glutamate. 
Contrary, our resnlts showed evidence for increased basal levels of extracellular brain 
glutamate. During both conditions, the veratridine- and potassium-evoked release of 
glutamate appeared unchanged. We concluded that encephalopathy from acute liver failure 
or acute hyperammonem.ia, is not caused by a glutamate deficit. Contrary, we found 
evidence for increased exposure of glutamate receptors to their ligand. 
How can increased extracellular brain glutamate levels induce encephalopathy? In 
theory, it could have two distinct effects; it could lead to down-regulation of glutamate 
receptors, or could have direct toxic effects. Binding of the ligand MK-801 to the MK-
801 binding site of the N-methyi-D-aspartate receptor was unchanged in both acute liver 
failure and acute hyperammonemia (chapter 4). 
In brain ischemia and epilepsy there is evidence indicating that prolonged 
glutamate exposure is deleterious to the brain. Prolonged glutamate exposure may lead to 
impaired ion homeostasis; especially increased calcium influx may be responsible for cell 
swelling and degeneration. We postulated that this mechanism could also be of importance 
in the pathogenesis of hepatic encephalopathy. However, using calcium-autoradiography 
we could not find increased calcium uptake in the brain of rabbits with encephalopathy 
from acute liver failure or acute hyperammonemia (chapter 5). In addition, there was no 
siginificant break-down of neuronal (neuron specific enolase, NF-68, NF-200) or glial 
(glial fibrillary protein, S-1 00) proteins, which are known to be increased after excitotoxic 
brain injury. 
In conclusion, ammonia appears to be of importance in the pathogenesis of hepatic 
encephalopathy. Experimental acute hyperammonemia resembles acute liver failure in 
many important aspects. Hepatic encephalopathy is not due to an ammonia induced 
glutamate deficit; contrary, the availability of glutamate in the extracellular space appears 
to be increased. However, this increase does not give rise to important excitoxic brain 
damage in our animal models. 
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SAMENVATTING 
In studies naar de pathogenese van hepatische encephalopathie, is ammoniak van 
begin af aan beschouwd als een belangrijk toxine. V anwege echter het ontbreken van een 
duidelijke correlatie tussen de plasma ammoniak spiegel en de mate van encepbalopathie, 
werd de ammoniak hypothese door velen verworpen. Sinds enige tijd staat de ammoniak 
hypothese weer in bet middelpunt van de belangstelling. 
Leslie Zieve heeft in bet begin van de jaren tachtig criteria opgesteld, analoog aan 
de postulaten van Koch, waaraan een substraat moet voldoen voordat het als relevant 
toxine in de pathogenese van hepatische encephalopathie kan worden beschouwd: (1) het 
toxine moet in verhoogde concentratie voorkomen bij patienten met hepatische 
encepbalopathie, (2) toediening van bet toxine moet encephalopathie veroorzaken en (3) 
verwijdering van het toxine moet leiden tot een vermindering van de encephalopatb.ie. 
Ammoniak blijkt grotendeels aan deze criteria te voldoen (hoofdstnk 1). Het doe! van dit 
proefschrift was bet bestuderen van het mechanisme van ammoniak-toxiciteit bij 
hepatische encephalopathie. 
Bij aanvang van het bier beschreven onderzoek, was een verstoring van het 
evenwicht tussen inhibitoire en excitatoire neurotransmitters een belangrijke hypothese. 
Ammoniak zou door remming van het enzym glutaminase, de synthese van de 
belangrijkste excitatoire neurotransmitter glutamaat blokkeren en zo encepbalopathie 
kunnen induceren. Vele studies leken dit te bevestigen, echter in de meeste van deze 
studies werd de glutamaatconcentratie in homogenaten bestudeerd, d.w.z. de sam van de 
concentraties in de extra- en intracellulaire ruimten. Neurotransmissie vindt plaats in de 
synaps, een onderdeel van de extracellulaire ruirnte. De hoeveelheid glutamaat in de 
extracellulaire ruirnte bedraagt minder dan 1 % van bet totale glutamaat aanwezig in de 
hersenen; meting van de hoeveelheid glutamaat in hersenhomogenaten geeft dan ook geen 
informatie over de beschikbaarheid van glutamaat voor neurotransmissie. Met behulp van 
hersendialyse, een techniek waarmee extracellulaire concentraties van laagmoleculaire 
stoffen ktmnen worden bestudeerd, wilden wij meer inzicht verkrijgen in de 
beschikbaarheid van glutamaat voor neurotransmissie, bij konijnen met acute 
leverinsufficientie en acute hyperammonemia. 
Om het mechanisme van armnoniak-toxiciteit bij hepatische encephalopathie te 
bestuderen, dient men over reproduceerbare diermodellen te beschikken. Wij maakten 
gebruik van konijnen met een acute ischemische levemecrose, en konijnen met een acute 
hyperammonemie, waarbij bet plasma ammoniak gebalte hetzelfde beloop heeft als bij 
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acute ischemische levernecrose. Deze diermodellen bleken in de praktijk zeer goed te 
functioneren (hoofdstuk 2). Bij aile konijnen ontstond encephalopathie, terwijl het aantal 
uitvallers buitengewoon laag was. Het klinische beeld van encephalopathie vertoonde 
belangrijke overeenkomsten. In beide modellen werd de encephalopathie gekarakteriseerd 
door verminderde activiteit, abnormale lichaamshouding, afwezigheid van de "righting 
reflex" en hypotonie. Encephalopathie ten gevolge van acute hyperammonemia werd 
bovendien gekarakteriseerd door ataxie, hetgeen slechts een enkele maal bij acute 
ischemische levernecrose werd gezien. Behoudens encephalopathie werden in beide 
modellen aanwijzingen gevonden voor cerebraal oedeem en lactaat acidose; 
nierinsufficientie, hypothennie en sepsis werden aileen bij acute ischemische levemecrose 
gevonden. 
In de cortex van konijnen met acute Ieverinsuffi.cientie en acute hyperammonemie 
werden geen aanwijzingen gevonden voor een tekort aan neurotransmitter glutamaat 
(hoofdstuk 3). Met behulp van continue dialyse, tijdens ontwikkeling van acute 
leverinsufficientie en acute hyperammonemie, vonden wij zelfs een toename van het 
glutamaatgehalte in het dialysaat (respectievelijk, een toename met een factor 2 en 1,7). 
De veratridine- en kalinm-geinduceerde afgifte van neurotransmitter glutamaat was ten 
opzichte van controle-konijnen niet afgenomen. Wij concludeerden, dat encephalopathie 
ten gevolge van acute leverinsufficientie en acute hyperammonemia niet gepaard gaat met 
een verminderde beschikbaarheid van glutamaat voor neurotransmissie. In tegendeel, wij 
menen dat de verhoogde glutamaat-concentraties duiden op een toegenomen bezetting van 
de glutamaatreceptoren. 
Hoe kan een verhoogde glutamaat concentratie in de extracelullaire rnimte 
encephalopathie veroorzaken? De theoretische mogelijkheden zijn een down-regulation 
van de glutamaatreceptoren of direct toxische effecten. In dezelfde diermodellen werden 
bindingsstudies met MK-801 uitgevoerd, een stof die selectief aan een belangrijke klasse 
glutamaat-receptoren bindt (N-methyi-D-aspartaat)(hoofdstuk 4). Noch bij acute 
leverinsufficientie, noch bij acute hyperammonem.ie werden veranderingen in de binding 
van J\.1K.-801 gevonden. 
De mogelijkheid van direct toxische effecten werd afgeleid uit de wetenschap dat 
bij hersenischemie een verhoogde extracellulaire cerebrale glutamaat concentratie voor 
een groat deel verantwoordelijk is voor de post-ischemische schade. Een verhoogde 
glutamaatconcentratie leidt tot een verhoogde intracellulaire calciumconcentratie, hetgeen 
toxisch en op den duur zelfs lethaal is voor een eel. Met behulp van calcinm-
autoradiografie konden wij geen verhoogde of afwijkende calcinmopname aantonen in de 
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hersenen van konijnen met encephalopathie als gevolg van acute leverinsufficientie of 
acute hyperammonernia (hoofdstuk 5). Bovendien vonden wij geen belangrijk afwijkende 
hoeveelheden afbraakproducten van neuronale en gliale eiwitten aantonen (neuron 
specifiek enolase, NF-68, NF-200, "glial fibrillary protein" en S-lOO)(hoofdstuk 6), die 
vrijkomen bij excitatoir gemedieerde beschadiging. 
Op grand van bovenstaande gegevens concluderen wij, dat ammoniak van be lang 
is voor het ontstaan van hepatische encephalopathie; ammoniak infusie leidt tot 
encephalopathie welke zeer veel overeenk.omsten vertoont met encephalopathie bij acute 
leverinsufficientie. Encephalopathie ten gevolge van acute leverinsufficientie en acute 
hyperammonemie gaat niet gepaard met een tekort aan neurotransmitter glutamaat; in 
tegendeel. de concentratie lijkt zelfs verhoogd. Echter, deze verhoging geeft geen 
aanleiding tot belangrijke glutamaattoxiciteit in de door ons bestudeerde tuodellen. 
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